UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-Q

(Mark One)

 \mathbf{X}

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 000-50976

HURON CONSULTING GROUP INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization) 01-0666114 (IRS Employer Identification Number)

550 West Van Buren Street Chicago, Illinois 60607 (Address of principal executive offices) (Zip Code)

(312) 583-8700

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.01 per share	HURN	NASDAQ Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes \boxtimes No \square

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes \boxtimes No \square

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company", and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer \boxtimes	Accelerated Filer		Non-accelerated Filer		Smaller Reporting Company		Emerging Growth Company	
-------------------------------------	-------------------	--	-----------------------	--	------------------------------	--	----------------------------	--

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes \Box No \boxtimes Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

As of October 26, 2021, 21,917,598 shares of the registrant's common stock, par value \$0.01 per share, were outstanding.

Huron Consulting Group Inc.

HURON CONSULTING GROUP INC.

INDEX

		Page
<u> Part I – Finan</u>	cial Information	
Item 1.	Consolidated Financial Statements (Unaudited)	
	Consolidated Balance Sheets	<u>1</u>
	Consolidated Statements of Operations and Other Comprehensive Income	1 2 3
	Consolidated Statements of Stockholders' Equity	<u>3</u>
	Consolidated Statements of Cash Flows	<u>4</u> 5
	Notes to Consolidated Financial Statements	<u>5</u>
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	<u>23</u>
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	<u>43</u>
Item 4.	Controls and Procedures	<u>44</u>
<u> Part II – Othe</u>	r Information	
Item 1.	Legal Proceedings	<u>44</u>
Item 1A.	Risk Factors	<u>44</u>
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	<u>45</u>
Item 3.	Defaults Upon Senior Securities	<u>45</u>
Item 4.	Mine Safety Disclosures	<u>45</u>
Item 5.	Other Information	<u>45</u>
Item 6.	Exhibits	<u>46</u>
<u>Signature</u>		<u>47</u>

PART I - FINANCIAL INFORMATION ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

HURON CONSULTING GROUP INC. CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) (Unaudited)

	Se	ptember 30, 2021	De	ecember 31, 2020
Assets	-			
Current assets:				
Cash and cash equivalents	\$	11,189	\$	67,177
Receivables from clients, net of allowances of \$8,236 and \$7,680, respectively		111,548		87,687
Unbilled services, net of allowances of \$2,738 and \$2,603, respectively		94,862		53,959
Income tax receivable		2,120		5,121
Prepaid expenses and other current assets		13,624		16,569
Total current assets		233,343		230,513
Property and equipment, net		30,654		29,093
Deferred income taxes, net		1,726		4,191
Long-term investments		68,216		71,030
Operating lease right-of-use assets		37,367		39,360
Other non-current assets		64,463		62,068
Intangible assets, net		16,663		20,483
Goodwill		597,552		594,237
Total assets	\$	1,049,984	\$	1,050,975
Liabilities and stockholders' equity				
Current liabilities:				
Accounts payable	\$	5,918	\$	648
Accrued expenses and other current liabilities		18,520		14,874
Accrued payroll and related benefits		103,526		133,830
Current maturities of long-term debt		555		499
Current maturities of operating lease liabilities		10,066		8,771
Deferred revenues		17,820		28,247
Total current liabilities		156,405		186,869
Non-current liabilities:				
Deferred compensation and other liabilities		40,582		47,131
Long-term debt, net of current portion		262,362		202,780
Operating lease liabilities, net of current portion		56,873		61,825
Deferred income taxes, net		394		428
Total non-current liabilities		360,211		312,164
Commitments and contingencies				
Stockholders' equity				
Common stock; \$0.01 par value; 500,000,000 shares authorized; 24,377,457 and 25,346,916 shares issued, respectively		238		246
Treasury stock, at cost, 2,457,456 and 2,584,119 shares, respectively		(135,903)		(129,886)
Additional paid-in capital		409,910		454,512
Retained earnings		245,938		214,009
Accumulated other comprehensive income		13,185		13,061
Total stockholders' equity		533,368		551,942
Total liabilities and stockholders' equity	\$	1,049,984	\$	1,050,975

The accompanying notes are an integral part of the consolidated financial statements.

HURON CONSULTING GROUP INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE INCOME (LOSS) (In thousands, except per share amounts) (Unaudited)

· ·	unet	, Three Mor Septen				Nine Mon Septen		
		2021		2020		2021		2020
Revenues and reimbursable expenses:								
Revenues	\$	224,007	\$	205,304	\$	657,346	\$	645,780
Reimbursable expenses		3,690		2,860		8,876		25,133
Total revenues and reimbursable expenses		227,697		208,164		666,222		670,913
Direct costs and reimbursable expenses (exclusive of depreciation an amortization shown in operating expenses):	b							
Direct costs		153,902		145,459		463,543		451,221
Amortization of intangible assets and software development costs		910		1,370		2,745		4,005
Reimbursable expenses		3,914		2,840		9,233		25,095
Total direct costs and reimbursable expenses		158,726		149,669		475,521		480,321
Operating expenses and other losses (gains), net								
Selling, general and administrative expenses		43,520		38,561		128,476		126,864
Restructuring charges		1,677		59		3,166		1,777
Litigation and other losses (gains)		56		—		98		(150)
Depreciation and amortization		5,412		6,176		16,286		18,483
Goodwill impairment charges								59,816
Total operating expenses and other losses (gains), net		50,665		44,796		148,026		206,790
Operating income (loss)		18,306		13,699		42,675		(16,198)
Other income (expense), net:								
Interest expense, net of interest income		(2,217)		(2,259)		(5,965)		(7,516)
Other income (expense), net		(394)		2,035		2,177		687
Total other expense, net		(2,611)		(224)		(3,788)		(6,829)
Income (loss) from continuing operations before taxes		15,695		13,475		38,887		(23,027)
Income tax expense (benefit)		1,968		2,388		6,958		(5,413)
Net income (loss) from continuing operations		13,727		11,087		31,929		(17,614)
Loss from discontinued operations, net of tax				(29)				(89)
Net income (loss)	\$	13,727	\$	11,058	\$	31,929	\$	(17,703)
Net earnings (loss) per basic share:		·		·				
Net income (loss) from continuing operations	\$	0.65	\$	0.50	\$	1.48	\$	(0.81)
Loss from discontinued operations, net of tax	•		+		Ŧ		÷	(0.02)
Net income (loss)	\$	0.65	\$	0.50	\$	1.48	\$	(0.81)
Net earnings (loss) per diluted share:		0.00	-	0.00	<u> </u>	2110	<u> </u>	(0:02)
Net earnings (loss) per unded share. Net income (loss) from continuing operations	\$	0.64	\$	0.50	\$	1.46	\$	(0.81)
Loss from discontinued operations, net of tax	Ψ	0.04	Ψ	0.50	Ψ	1.40	Ψ	(0.01)
Net income (loss)	\$	0.64	\$	0.50	\$	1.46	\$	(0.81)
	φ	0.04	Ψ	0.50	φ	1.40	φ	(0.81)
Weighted average shares used in calculating earnings (loss) per share:		21 242		21.005				21.000
Basic		21,242		21,905		21,574		21,868
Diluted		21,531		22,175		21,904		21,868
Comprehensive income (loss):	¢	10 707	¢	11 050	ተ	21 020	¢	(17 702)
Net income (loss) Foreign currency translation adjustments, net of tax	\$		\$	11,058 381	\$	31,929	\$	(17,703)
		(246)				236		(294)
Unrealized gain (loss) on investment, net of tax		1,158		4,885		(2,068)		(1,051)
Unrealized gain (loss) on cash flow hedging instruments, net of tax		309		(243)		1,956		(3,633)
Other comprehensive income (loss)	*	1,221	<u>+</u>	5,023	<u>_</u>	124	*	(4,978)
Comprehensive income (loss)	\$	14,948	\$	16,081	\$	32,053	\$	(22,681)

The accompanying notes are an integral part of the consolidated financial statements.

HURON CONSULTING GROUP INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (In thousands, except share amounts) (Unaudited)

					1	Three Month	s En	ided Septer	nber	· 30,				
	Commo Shares		ck mount	Treasu Shares	ry S	itock Amount		dditional Paid-In Capital		Retained Earnings		ccumulated Other Comprehensive Income	St	ockholders' Equity
Balance at June 30, 2021	24,321,728	\$	243	(2,899,933)	\$	(135,364)	\$	429,084	\$	232,211	\$	11,964	\$	538,138
Comprehensive income	24,021,120	Ŷ	240	(2,000,000)	Ψ	(100,004)	Ψ	420,004	Ψ	13,727	Ψ	1,221	Ŷ	14,948
Issuance of common stock in connection with:										,		_,		,c . c
Restricted stock awards, net of cancellations	45,190		_	1,371		77		(77)						_
Exercise of stock options	5,000		—					191						191
Share-based compensation								5,693						5,693
Shares redeemed for employee tax withholdings				(12,489)		(616)								(616)
Share repurchases	(518,045)		(5)					(24,981)						(24,986)
Balance at September 30, 2021	23,853,873	\$	238	(2,911,051)	\$	(135,903)	\$	409,910	\$	245,938	\$	13,185	\$	533,368
Balance at June 30, 2020	24,586,236	\$	246	(2,786,798)	\$	(128,646)	\$	450,391	\$	209,088	\$	4,935		536,014
Comprehensive income										11,058		5,023		16,081
Issuance of common stock in connection with:														
Restricted stock awards, net of cancellations	51,860		1	(4,130)		(212)		211						_
Exercise of stock options	6,800		_					179						179
Share-based compensation								3,372						3,372
Shares redeemed for employee tax withholdings				(12,468)		(580)								(580)
Balance at September 30, 2020	24,644,896	\$	247	(2,803,396)	\$	(129,438)	\$	454,153	\$	220,146	\$	9,958	\$	555,066
		<u> </u>	271	(2,000,000)		(120, 100)	-			-, -	_	- ,		
				(2,000,000)	_		_		hor		-	- ,	-	,
						Nine Months	s En	ded Septen	ber					
	Commo	on Sto	ck	Treasu		Nine Months itock	s End Ad	ded Septen dditional Paid-In	F	30, Retained		ccumulated Other Comprehensive		ockholders'
	Shares	on Sto A	ck mount	Treasu	ry S	Nine Months itock Amount	s End Ad	ded Septen dditional Paid-In Capital	F	30, Retained Earnings		ccumulated Other Comprehensive Income	St	ockholders' Equity
Balance at December 31, 2020		on Sto	ck	Treasu		Nine Months itock	s End Ad	ded Septen dditional Paid-In	F	30, Retained Earnings 214,009		ccumulated Other Comprehensive Income 13,061		ockholders' Equity 551,942
Comprehensive income	Shares	on Sto A	ck mount	Treasu	ry S	Nine Months itock Amount	s End Ad	ded Septen dditional Paid-In Capital	F	30, Retained Earnings		ccumulated Other Comprehensive Income	St	ockholders' Equity
Comprehensive income Issuance of common stock in connection with:	Shares	on Sto A	ck mount	Treasu	ry S	Nine Months itock Amount	s End Ad	ded Septen dditional Paid-In Capital	F	30, Retained Earnings 214,009		ccumulated Other Comprehensive Income 13,061	St	ockholders' Equity 551,942
Comprehensive income Issuance of common stock in connection with: Restricted stock awards, net of cancellations	Shares 24,560,855 443,741	on Sto A	ck mount	Treasu	ry S	Nine Months itock Amount	s End Ad	ded Septen dditional Paid-In Capital 454,512 (3,254)	F	30, Retained Earnings 214,009		ccumulated Other Comprehensive Income 13,061	St	ockholders' Equity 551,942 32,053
Comprehensive income Issuance of common stock in connection with: Restricted stock awards, net of cancellations Exercise of stock options	Shares 24,560,855	on Sto A	ck mount 246	Treasu Shares (2,812,896)	ry S	Nine Months itock Amount (129,886)	s End Ad	ded Septen dditional Paid-In Capital 454,512 (3,254) 613	F	30, Retained Earnings 214,009		ccumulated Other Comprehensive Income 13,061	St	ockholders' Equity 551,942 32,053 613
Comprehensive income Issuance of common stock in connection with: Restricted stock awards, net of cancellations Exercise of stock options Share-based compensation	Shares 24,560,855 443,741	on Sto A	ck mount 246	Treasu Shares (2,812,896)	ry S	Nine Months itock Amount (129,886)	s End Ad	ded Septen dditional Paid-In Capital 454,512 (3,254)	F	30, Retained Earnings 214,009		ccumulated Other Comprehensive Income 13,061	St	ockholders' Equity 551,942 32,053
Comprehensive income Issuance of common stock in connection with: Restricted stock awards, net of cancellations Exercise of stock options Share-based compensation Shares redeemed for employee tax	Shares 24,560,855 443,741	on Sto A	ck mount 246	Treasu Shares (2,812,896) 82,380	ry S	Nine Months tock Amount (129,886) 3,250	s End Ad	ded Septen dditional Paid-In Capital 454,512 (3,254) 613	F	30, Retained Earnings 214,009		ccumulated Other Comprehensive Income 13,061	St	ockholders' Equity 551,942 32,053 — 613 18,256
Comprehensive income Issuance of common stock in connection with: Restricted stock awards, net of cancellations Exercise of stock options Share-based compensation Shares redeemed for employee tax withholdings	Shares 24,560,855 443,741 18,403	on Sto A	ck mount 246 4 	Treasu Shares (2,812,896)	ry S	Nine Months itock Amount (129,886)	s End Ad	ded Septen dditional Paid-In Capital 454,512 (3,254) 613 18,256	F	30, Retained Earnings 214,009		ccumulated Other Comprehensive Income 13,061	St	ockholders' Equity 551,942 32,053
Comprehensive income Issuance of common stock in connection with: Restricted stock awards, net of cancellations Exercise of stock options Share-based compensation Shares redeemed for employee tax withholdings Share repurchases	Shares 24,560,855 443,741 18,403 (1,169,126)	n Sto A \$	ck mount 246 4 (12)	Treasur Shares (2,812,896) 82,380 (180,535)	= ry S \$	Nine Months tock Amount (129,886) 3,250 (9,267)	s End Ad \$	ded Septen dditional Paid-In Capital 454,512 (3,254) 613 18,256 (60,217)	\$	30, Retained arnings 214,009 31,929	\$	ccumulated Other Comprehensive Income 13,061 124	Sta \$	ockholders' Equity 551,942 32,053
Comprehensive income Issuance of common stock in connection with: Restricted stock awards, net of cancellations Exercise of stock options Share-based compensation Shares redeemed for employee tax withholdings	Shares 24,560,855 443,741 18,403	on Sto A	ck mount 246 4 	Treasu Shares (2,812,896) 82,380	ry S	Nine Months tock Amount (129,886) 3,250	s End Ad	ded Septen dditional Paid-In Capital 454,512 (3,254) 613 18,256	F	30, Retained Earnings 214,009		ccumulated Other Comprehensive Income 13,061	St	ockholders' Equity 551,942 32,053
Comprehensive income Issuance of common stock in connection with: Restricted stock awards, net of cancellations Exercise of stock options Share-based compensation Shares redeemed for employee tax withholdings Share repurchases	Shares 24,560,855 443,741 18,403 (1,169,126)	n Sto A \$	ck mount 246 4 (12)	Treasur Shares (2,812,896) 82,380 (180,535)	= ry S \$	Nine Months tock Amount (129,886) 3,250 (9,267)	s End Ad \$	ded Septen dditional Paid-In Capital 454,512 (3,254) 613 18,256 (60,217)	\$	30, Retained arnings 214,009 31,929	\$	ccumulated Other Comprehensive Income 13,061 124	Sta \$	ockholders' Equity 551,942 32,053 613 18,256 (9,267) (60,229)
Comprehensive income Issuance of common stock in connection with: Restricted stock awards, net of cancellations Exercise of stock options Share-based compensation Shares redeemed for employee tax withholdings Share repurchases Balance at September 30, 2021	Shares 24,560,855 443,741 18,403 (1,169,126) 23,853,873	n Sto A \$	ck mount 246 4 (12) 238	Treasu Shares (2,812,896) 82,380 (180,535) (2,911,051)	= ry S \$ \$	Nine Months tock Amount (129,886) 3,250 (9,267) (135,903)	\$ End A \$	ded Septen dditional Paid-In Capital 454,512 (3,254) 613 18,256 (60,217) 409,910	\$	30, Retained annings 214,009 31,929 245,938	\$	ccumulated Other Comprehensive 13,061 124 124 13,185	\$	ockholders' Equity 551,942 32,053 613 18,256 (9,267) (60,229) 533,368
Comprehensive income Issuance of common stock in connection with: Restricted stock awards, net of cancellations Exercise of stock options Shares redeemed for employee tax withholdings Share repurchases Balance at September 30, 2021 Balance at December 31, 2019 Comprehensive loss Issuance of common stock in connection with:	Shares 24,560,855 443,741 18,403 (1,169,126) 23,853,873	n Sto A \$	ck mount 246 4 (12) 238	Treasu Shares (2,812,896) 82,380 (180,535) (2,911,051)	= ry S \$ \$	Nine Months tock Amount (129,886) 3,250 (9,267) (135,903)	\$ End A \$	ded Septen dditional Paid-In Capital 454,512 (3,254) 613 18,256 (60,217) 409,910	\$	30, Retained annings 214,009 31,929 2145,938 245,938 237,849	\$	ccumulated Other Comprehensive 13,061 124 124 13,185 14,936	\$	ockholders' Equity 551,942 32,053 613 18,256 (9,267) (60,229) 533,368 585,465
Comprehensive income Issuance of common stock in connection with: Restricted stock awards, net of cancellations Exercise of stock options Share-based compensation Shares redeemed for employee tax withholdings Share repurchases Balance at September 30, 2021 Balance at December 31, 2019 Comprehensive loss Issuance of common stock in connection with: Restricted stock awards, net of cancellations	Shares 24,560,855 443,741 18,403 (1,169,126) 23,853,873	n Sto A \$	ck mount 246 4 (12) 238	Treasu Shares (2,812,896) 82,380 (180,535) (2,911,051)	= ry S \$ \$	Nine Months tock Amount (129,886) 3,250 (9,267) (135,903)	\$ End A \$	ded Septen dditional Paid-In Capital 454,512 (3,254) 613 18,256 (60,217) 409,910	\$	30, Retained annings 214,009 31,929 2145,938 245,938 237,849	\$	ccumulated Other Comprehensive 13,061 124 124 13,185 14,936	\$	ockholders' Equity 551,942 32,053 613 18,256 (9,267) (60,229) 533,368 585,465
Comprehensive income Issuance of common stock in connection with: Restricted stock awards, net of cancellations Exercise of stock options Share-based compensation Shares redeemed for employee tax withholdings Share repurchases Balance at September 30, 2021 Balance at December 31, 2019 Comprehensive loss Issuance of common stock in connection with: Restricted stock awards, net	Shares 24,560,855 443,741 18,403 (1,169,126) 23,853,873 24,603,308	n Sto A \$	ck mount 246 4 (12) 238 247	Treasu Shares (2,812,896) 82,380 (180,535) (2,911,051) (2,763,302)	= ry S \$ \$	Nine Months tock Amount (129,886) 3,250 (9,267) (135,903) (128,348)	\$ End A \$	ded Septen dditional Paid-In Capital 454,512 (3,254) 613 18,256 (60,217) 409,910 460,781 (6,710) 825	\$	30, Retained annings 214,009 31,929 2145,938 245,938 237,849	\$	ccumulated Other Comprehensive 13,061 124 124 13,185 14,936	\$	ockholders' Equity 551,942 32,053 613 18,256 (9,267) (60,229) 533,368 585,465 (22,681) 825
Comprehensive income Issuance of common stock in connection with: Restricted stock awards, net of cancellations Exercise of stock options Share-based compensation Shares redeemed for employee tax withholdings Share repurchases Balance at September 30, 2021 Balance at December 31, 2019 Comprehensive loss Issuance of common stock in connection with: Restricted stock awards, net of cancellations	Shares 24,560,855 443,741 18,403 (1,169,126) 23,853,873 24,603,308 321,986	n Sto A \$	ck mount 246 4 (12) 238 247	Treasu Shares (2,812,896) 82,380 (180,535) (2,911,051) (2,763,302)	= ry S \$ \$	Nine Months tock Amount (129,886) 3,250 (9,267) (135,903) (128,348)	\$ End A \$	ded Septen dditional Paid-in Capital 454,512 (3,254) 613 18,256 (60,217) 409,910 460,781 (6,710)	\$	30, Retained annings 214,009 31,929 2145,938 245,938 237,849	\$	ccumulated Other Comprehensive 13,061 124 124 13,185 14,936	\$	ockholders' Equity 551,942 32,053 613 18,256 (9,267) (60,229) 533,368 585,465 (22,681)
Comprehensive income Issuance of common stock in connection with: Restricted stock awards, net of cancellations Exercise of stock options Share-based compensation Shares redeemed for employee tax withholdings Share repurchases Balance at September 30, 2021 Balance at September 31, 2019 Comprehensive loss Issuance of common stock in connection with: Restricted stock awards, net of cancellations Exercise of stock options Share-based compensation Shares redeemed for employee tax withholdings	Shares 24,560,855 443,741 18,403 (1,169,126) 23,853,873 24,603,308 321,986 33,600	n Sto A \$	ck mount 246 4 (12) 238 247 3	Treasu Shares (2,812,896) 82,380 (180,535) (2,911,051) (2,763,302)	= ry S \$ \$	Nine Months tock Amount (129,886) 3,250 (9,267) (135,903) (128,348)	\$ End A \$	ded Septen dditional Paid-In Capital 454,512 (3,254) 613 18,256 (60,217) 409,910 460,781 (6,710) 825 20,135	\$	30, Retained annings 214,009 31,929 2145,938 245,938 237,849	\$	ccumulated Other Comprehensive 13,061 124 124 13,185 14,936	\$	ockholders' Equity 551,942 32,053 (613 18,256 (9,267) (60,229) 533,368 585,465 (22,681)
Comprehensive income Issuance of common stock in connection with: Restricted stock awards, net of cancellations Exercise of stock options Share-based compensation Shares redeemed for employee tax withholdings Share repurchases Balance at September 30, 2021 Balance at December 31, 2019 Comprehensive loss Issuance of common stock in connection with: Restricted stock awards, net of cancellations Exercise of stock options Share-based compensation Shares redeemed for employee tax	Shares 24,560,855 443,741 18,403 (1,169,126) 23,853,873 24,603,308 321,986 33,600	n Sto A \$	ck mount 246 4 (12) 238 247	Treasun Shares (2,812,896) 82,380 (180,535) (2,911,051) (2,763,302) 94,180	= ry S \$ \$	Nine Months tock Amount (129,886) 3,250 (9,267) (135,903) (128,348) 6,707	\$ End A \$	ded Septen dditional Paid-In Capital 454,512 (3,254) 613 18,256 (60,217) 409,910 460,781 (6,710) 825	\$	30, Retained annings 214,009 31,929 2145,938 245,938 237,849	\$	ccumulated Other Comprehensive 13,061 124 124 13,185 14,936	\$	ockholders' Equity 551,942 32,053 613 18,256 (9,267) (60,229) 533,368 585,465 (22,681) 825 20,135

The accompanying notes are an integral part of the consolidated financial statements.

3

HURON CONSULTING GROUP INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited)

	Nine Months Ended September 30,			
	2021		2020	
Cash flows from operating activities:				
Net income (loss)	\$ 31,92	9 \$	(17,703)	
Adjustments to reconcile net income (loss) to cash flows from operating activities:				
Depreciation and amortization	19,24		22,511	
Non-cash lease expense	4,91		5,844	
Share-based compensation	17,97	9	18,559	
Amortization of debt discount and issuance costs	59	5	595	
Goodwill impairment charges	-	-	59,816	
Allowances for doubtful accounts	-	-	539	
Deferred income taxes	2,43	4	(16,125	
Loss on sale of business	-	-	102	
Change in fair value of contingent consideration liabilities	9	8		
Other, net	(32	5)		
Changes in operating assets and liabilities, net of acquisition and divestiture:				
(Increase) decrease in receivables from clients, net	(23,29	4)	23,493	
(Increase) decrease in unbilled services, net	(40,88	3)	1,597	
(Increase) decrease in current income tax receivable / payable, net	3,15	9	9,455	
(Increase) decrease in other assets	9		(3,426	
Increase (decrease) in accounts payable and other liabilities	2,22	9	(5,272	
Increase (decrease) in accrued payroll and related benefits	(35,95	8)	(25,290	
Increase (decrease) in deferred revenues	(10,42	4)	3,290	
Net cash provided by (used in) operating activities	(28,20	6)	77,985	
Cash flows from investing activities:				
Purchases of property and equipment, net	(8,91	8)	(5,731	
Purchase of investment securities	-	-	(13,000	
Investment in life insurance policies	(57	,	(2,026	
Purchase of business	(5,88	6)	(801	
Capitalization of internally developed software costs	(3,60	3)	(6,830	
Proceeds from sale of property and equipment	25	5		
Net cash used in investing activities	(18,72	6)	(28,388	
Cash flows from financing activities:				
Proceeds from exercises of stock options	61	3	825	
Shares redeemed for employee tax withholdings	(9,26	7)	(7,797	
Share repurchases	(60,22	9)	(22,115	
Proceeds from bank borrowings	189,00	0	283,000	
Repayments of bank borrowings	(129,36	2)	(240,396	
Net cash provided by (used in) financing activities	(9,24	5)	13,517	
Effect of exchange rate changes on cash	18	9	27	
Net increase (decrease) in cash and cash equivalents	(55,98	8)	63,141	
Cash and cash equivalents at beginning of the period	67,17	7	11,604	
Cash and cash equivalents at end of the period	\$ 11,18	9 \$	74,745	
Supplemental disclosure of cash flow information:				
Non-cash investing and financing activities:				
Property and equipment expenditures and capitalized software included in accounts payable, accrued	1			
expenses and accrued payroll and related benefits	\$ 2,14	0 \$	2,049	
Operating lease right-of-use asset obtained in exchange for operating lease liability	\$ 2,96	0 \$	1,456	

The accompanying notes are an integral part of the consolidated financial statements.

1. Description of Business

Huron is a global consultancy that collaborates with clients to drive strategic growth, ignite innovation and navigate constant change. Through a combination of strategy, expertise and creativity, we help clients accelerate operational, digital and cultural transformation, enabling the change they need to own their future. By embracing diverse perspectives, encouraging new ideas and challenging the status quo, Huron creates sustainable results for the organizations it serves.

2. Basis of Presentation and Significant Accounting Policies

The accompanying unaudited consolidated financial statements reflect the financial position, results of operations, and cash flows as of and for the three and nine months ended September 30, 2021 and 2020. These financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") for Quarterly Reports on Form 10-Q. Accordingly, these financial statements do not include all of the information and note disclosures required by accounting principles generally accepted in the United States of America ("GAAP") for annual financial statements. In the opinion of management, these financial statements reflect all adjustments of a normal, recurring nature necessary for the fair statement of our financial position, results of operations, and cash flows for the interim periods presented in conformity with GAAP. These financial statements should be read in conjunction with our consolidated financial statements and notes thereto for the year ended December 31, 2020 included in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q for the periods ended March 31, 2021 and June 30, 2021. Our results for any interim period are not necessarily indicative of results for a full year or any other interim period.

During the first quarter of 2021, we identified an error on our previously reported consolidated balance sheet as of December 31, 2020 related to the classification between receivables from clients, unbilled services, and deferred revenues. Our consolidated balance sheet as of December 31, 2020 presented herein has been revised to reflect the correction of this error. The results of this correction on our consolidated balance sheet were a decrease in unbilled services of \$7.2 million, an increase in receivables from clients of \$0.7 million, and a decrease in deferred revenues of \$6.5 million. This error had no impact on our consolidated statement of operations and other comprehensive income and consolidated statements of cash flows for any current or prior period. We evaluated the materiality of this error from both quantitative and qualitative perspectives and concluded that the impact of the error was not material to the financial statements for the year ended December 31, 2020.

Preparation of our consolidated financial statements requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and related disclosures. The business and economic uncertainty resulting from the coronavirus (COVID-19) pandemic has made such estimates and assumptions more difficult to predict. Accordingly, actual results and outcomes could differ from those estimates.

3. New Accounting Pronouncements

Recently Adopted

In October 2020, the FASB issued Accounting Standards Update ("ASU") 2020-10, *Codification Improvements*. ASU 2020-10 situates all disclosure guidance within the appropriate disclosure section of the Codification and makes other improvements and technical corrections to the Codification. We adopted ASU 2020-10 effective January 1, 2021, which did not have any impact on our consolidated financial statements.

Not Yet Adopted

In March 2020, the FASB issued ASU 2020-04, *Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.* In January 2021, the FASB clarified the scope of that guidance with the issuance of ASU 2021-01, *Reference Rate Reform (Topic 848): Scope.* Together, these ASUs provide optional expedients and exceptions for a limited period of time to ease the potential burden in accounting for, or recognizing the effects of, reference rate reform on financial reporting under GAAP. This standard is optional and may be applied by entities after March 12, 2020, but no later than December 31, 2022. We have certain debt instruments and related interest rate swaps that are indexed to LIBOR; as such, we are currently evaluating the potential impact this guidance will have on our consolidated financial statements.

4. Goodwill and Intangible Assets

The table below sets forth the changes in the carrying amount of goodwill by reportable segment for the nine months ended September 30, 2021.

	Healthcare	Business Advisory	Education	Total
Balance as of December 31, 2020:				
Goodwill	\$ 636,810	\$ 308,935	\$ 104,384	\$ 1,050,129
Accumulated impairment losses	(208,081)	(247,811)	_	(455,892)
Goodwill, net as of December 31, 2020	 428,729	 61,124	 104,384	 594,237
Goodwill recorded in connection with a business acquisition ⁽¹⁾		3,315		3,315
Goodwill, net as of September 30, 2021	\$ 428,729	\$ 64,439	\$ 104,384	\$ 597,552

(1) On February 1, 2021, we completed the acquisition of Unico Solution, a data strategy and technology consulting firm focused on helping clients use their data to speed business transformation and accelerate cloud adoption. The results of operations of Unico Solution are included in our consolidated financial statements and results of operations of our Business Advisory segment from the date of acquisition. This acquisition is not significant to our consolidated financial statements.

First Quarter 2020 Goodwill Impairment Charges

The worldwide spread of the COVID-19 pandemic in the first quarter of 2020 created significant volatility, uncertainty and disruption to the global economy. From the onset of the COVID-19 pandemic, we closely monitored the impact it could have on all aspects of our business, including how we expect it to negatively impact our clients, employees and business partners. While the COVID-19 pandemic did not have a significant impact on our consolidated revenues in the first quarter of 2020, we expected it to have an unfavorable impact on sales, increase uncertainty in the backlog and negatively impact full year 2020 results. The services provided by our Strategy and Innovation and Life Sciences reporting units within our Business Advisory segment focus on strategic solutions for healthy, well-capitalized companies to identify new growth opportunities, which may be considered by our clients to be more discretionary in nature, and the duration of the projects within these practices are typically short-term. Therefore, at the onset of the COVID-19 pandemic in the U.S. and due to the uncertainty caused by the pandemic, we were cautious about near-term results for these two reporting units. Based on our internal projections and the preparation of our financial statements for the quarter ended March 31, 2020, and considering the expected decrease in demand due to the COVID-19 pandemic, during the first quarter of 2020 we believed it was more likely than not that the fair value of these two reporting units no longer exceeded their carrying values and performed an interim impairment test on both reporting units as of March 31, 2020.

Based on the estimated fair values of the Strategy and Innovation and Life Sciences reporting units, we recorded non-cash pretax goodwill impairment charges of \$49.9 million and \$9.9 million, respectively, in the first quarter of 2020. The \$49.9 million non-cash pretax charge related to the Strategy and Innovation reporting unit reduced the goodwill balance of the reporting unit to \$37.5 million. The \$9.9 million non-cash pretax charge related to the Life Sciences reporting unit reduced the goodwill balance of the reporting unit to zero.

Our goodwill impairment test was performed by comparing the fair value of each of the Strategy and Innovation and Life Sciences reporting units with its respective carrying value and recognizing an impairment charge for the amount by which the carrying value exceeded the fair value. To estimate the fair value of each reporting unit, we relied on a combination of the income approach and the market approach with a fifty-fifty weighting.

In the income approach, we utilized a discounted cash flow analysis, which involved estimating the expected after-tax cash flows that will be generated by each reporting unit and then discounting those cash flows to present value, reflecting the relevant risks associated with each reporting unit and the time value of money. This approach requires the use of significant estimates and assumptions, including forecasted revenue growth rates, forecasted EBITDA margins, and discount rates that reflect the risk inherent in the future cash flows. In estimating future cash flows, we relied on internally generated seven-year forecasts. Our forecasts are based on historical experience, current backlog, expected market demand, and other industry information.

In the market approach, we utilized the guideline company method, which involved calculating revenue multiples based on operating data from guideline publicly traded companies. Multiples derived from guideline companies provide an indication of how much a knowledgeable investor in the marketplace would be willing to pay for a company. These multiples were evaluated and adjusted based on specific characteristics of the Strategy and Innovation and Life Sciences reporting units relative to the selected guideline companies and applied to the reporting units' operating data to arrive at an indication of value.

Intangible Assets

Intangible assets as of September 30, 2021 and December 31, 2020 consisted of the following:

		As of September 30, 2021			As of Decen	nber 31, 2020		
	Useful Life (in years)	 Gross Carrying Amount		ccumulated mortization	 Gross Carrying Amount		Accumulated	
Customer relationships	3 to 13	\$ 71,273	\$	56,496	\$ 73,629	\$	56,232	
Trade names	6	6,000		4,901	6,130		4,287	
Technology and software	5	5,800		5,543	5,800		5,380	
Non-competition agreements	5	1,720		1,258	2,090		1,541	
Customer contracts	2	800		732	800		526	
Total		\$ 85,593	\$	68,930	\$ 88,449	\$	67,966	

Identifiable intangible assets with finite lives are amortized over their estimated useful lives. Customer relationships and customer contracts, as well as certain trade names and technology and software, are amortized on an accelerated basis to correspond to the cash flows expected to be derived from the assets. All other intangible assets with finite lives are amortized on a straight-line basis.

Intangible asset amortization expense was \$2.2 million and \$3.2 million for the three months ended September 30, 2021 and 2020, respectively; and \$6.9 million and \$9.6 million for the nine months ended September 30, 2021 and 2020. The table below sets forth the estimated annual amortization expense for the intangible assets recorded as of September 30, 2021.

Year E	nding December 31,	Amortization ense ⁽¹⁾
2021		\$ 9,059
2022		\$ 6,878
2023		\$ 4,231
2024		\$ 1,384
2025		\$ 566

(1) On November 1, 2021, we completed the divestiture of the Life Sciences business, including the sale of customer relationships previously acquired which had a net book value of \$2.0 million as of September 30, 2021. The amortization of these customer relationships is included in the table above through 2024.

Actual future amortization expense could differ from these estimated amounts as a result of future acquisitions, dispositions, and other factors.

5. Revenues

For the three months ended September 30, 2021 and 2020, we recognized revenues of \$224.0 million and \$205.3 million, respectively. Of the \$224.0 million recognized in the third quarter of 2021, we recognized revenues of \$4.3 million from obligations satisfied, or partially satisfied, in prior periods, of which \$2.2 million was primarily due to the release of allowances on unbilled services and \$2.1 million was due to changes in the estimates of our variable consideration under performance-based billing arrangements. Of the \$205.3 million recognized in the third quarter of 2020, we recognized revenues of \$7.4 million from obligations satisfied, or partially satisfied, in prior periods, of which \$5.7 million was primarily due to the release on unbilled services and \$1.7 million was due to changes in the estimates of our variable consideration under performance.

For the nine months ended September 30, 2021 and 2020, we recognized revenues of \$657.3 million and \$645.8 million, respectively. Of the \$657.3 million recognized in the first nine months of 2021, we recognized revenues of \$22.1 million from obligations satisfied, or partially satisfied, in prior periods, of which \$14.6 million was due to changes in the estimates of our variable consideration under performance-based billing arrangements and \$7.5 million was primarily due to the release of allowances on unbilled services. Of the \$645.8 million recognized in the first nine months of 2020, we recognized revenues of \$11.0 million from obligations satisfied, in prior periods, of which \$6.5 million was due to changes in the estimates of our variable consideration under performance-based billing arrangements and \$4.5 million was due to changes in the estimates of our variable consideration under performance-based billing arrangements and \$4.5 million was due to changes on unbilled services.

As of September 30, 2021, we had \$72.8 million of remaining performance obligations under engagements with original expected durations greater than one year. These remaining performance obligations exclude obligations under contracts with an original expected duration of one year or less, variable consideration which has been excluded from the total transaction price due to the constraint, and performance obligations under time-and-expense engagements which are recognized in the amount invoiced. Of the \$72.8 million of performance obligations, we expect to recognize approximately \$15.8 million as revenue in 2021, \$30.2 million in 2022, and the remaining \$26.8 million thereafter. Actual revenue recognition could differ from these amounts as a result of changes in the estimated timing of work to be performed, adjustments to estimated variable consideration in performance-based arrangements, or other factors.

Contract Assets and Liabilities

The payment terms and conditions in our customer contracts vary. Differences between the timing of billings and the recognition of revenue are recognized as either unbilled services or deferred revenues in the consolidated balance sheets.

Unbilled services include revenues recognized for services performed but not yet billed to clients. Services performed that we are not yet entitled to bill because certain events, such as the completion of the measurement period or client approval in performance-based engagements, must occur are recorded as contract assets and included within unbilled services, net. The contract asset balance as of September 30, 2021 and December 31, 2020 was \$20.8 million and \$17.3 million, respectively. The \$3.5 million increase primarily reflects timing differences between the completion of our performance obligations and the amounts billed or billable to clients in accordance with their contractual billing terms.

Client prepayments and retainers are classified as deferred revenues and recognized over future periods in accordance with the applicable engagement agreement and our revenue recognition policy. Our deferred revenues balance as of September 30, 2021 and December 31, 2020, was \$17.8 million and \$28.2 million, respectively. The \$10.4 million decrease primarily reflects timing differences between client payments in accordance with their contract terms and the completion of our performance obligations. For the three and nine months ended September 30, 2021, \$1.3 million and \$27.3 million of revenues recognized were included in the deferred revenue balance as of December 31, 2020.

8

6. Earnings Per Share

Basic earnings per share excludes dilution and is computed by dividing net income by the weighted average number of common shares outstanding for the period, excluding unvested restricted common stock. Diluted earnings per share reflects the potential reduction in earnings per share that could occur if securities or other contracts to issue common stock were exercised or converted into common stock under the treasury stock method. Such securities or other contracts include unvested restricted stock awards, unvested restricted stock units, and outstanding common stock options, to the extent dilutive. In periods for which we report a net loss from continuing operations, diluted weighted average common shares outstanding excludes all potential common stock equivalents as their impact on diluted net loss from continuing operations per share would be anti-dilutive.

Earnings (loss) per share under the basic and diluted computations are as follows:

	Three Mor Septen		Nine Months Ended September 30,				
	 2021		2020		2021		2020
Net income (loss) from continuing operations	\$ 13,727	\$	11,087	\$	31,929	\$	(17,614)
Loss from discontinued operations, net of tax	—		(29)		—		(89)
Net income (loss)	\$ 13,727	\$	11,058	\$	31,929	\$	(17,703)
				_		_	
Weighted average common shares outstanding – basic	21,242		21,905		21,574		21,868
Weighted average common stock equivalents	289		270		330		—
Weighted average common shares outstanding – diluted	21,531		22,175		21,904		21,868
Net earnings (loss) per basic share:							
Net income (loss) from continuing operations	\$ 0.65	\$	0.50	\$	1.48	\$	(0.81)
Loss from discontinued operations, net of tax	 		—		—		—
Net income (loss)	\$ 0.65	\$	0.50	\$	1.48	\$	(0.81)
Net earnings (loss) per diluted share:							
Net income (loss) from continuing operations	\$ 0.64	\$	0.50	\$	1.46	\$	(0.81)
Loss from discontinued operations, net of tax			—		—		
Net income (loss)	\$ 0.64	\$	0.50	\$	1.46	\$	(0.81)

The number of anti-dilutive securities excluded from the computation of the weighted average common stock equivalents presented above were less than 0.1 million shares at both September 30, 2021 and 2020, and related to unvested restricted stock.

In November 2020, our board of directors authorized a share repurchase program (the "2020 Share Repurchase Program") permitting us to repurchase up to \$50 million of our common stock through December 31, 2021. The 2020 Share Repurchase Program was authorized subsequent to the expiration of our prior share repurchase program (the "2015 Share Repurchase Program") on October 31, 2020. The 2015 Share Repurchase Program permitted us to repurchase up to \$125 million of our common stock through October 31, 2020. The 2015 Share Repurchase Program directors authorized an extension of the 2020 Share Repurchase Program through December 31, 2022 and increased the authorized amount from \$50 million to \$100 million. The amount and timing of repurchases under both share repurchase programs were and will continue to be determined by management and depend on a variety of factors, including the trading price of our common stock, capacity under our credit facility, general market and business conditions, and applicable legal requirements. All shares repurchase and retired are reflected as a reduction to our basic weighted average shares outstanding based on the trade date of the share repurchase.

In the three and nine months ended September 30, 2021, we repurchased and retired 518,045 and 1,169,126 shares for \$25.0 million and \$60.2 million, respectively, under the 2020 Share Repurchase Program. In the first quarter of 2020, we repurchased 313,998 shares for \$20.9 million under the 2015 Share Repurchase Program. Additionally, in the first quarter of 2020, we settled the repurchase of 18,000 shares for \$1.2 million that were accrued as of December 31, 2019. No shares were repurchased in the second or third quarters of 2020. As of September 30, 2021, \$34.7 million remained available for share repurchases under our 2020 Share Repurchase Program.

7. Financing Arrangements

A summary of the carrying amounts of our debt follows:

	September 30, 2021	December 31, 2020
Senior secured credit facility	\$ 260,000	\$ 200,000
Promissory note due 2024	2,917	3,279
Total long-term debt	\$ 262,917	\$ 203,279
Current maturities of long-term debt	(555)	(499)
Long-term debt, net of current portion	\$ 262,362	\$ 202,780

Below is a summary of the scheduled remaining principal payments of our debt as of September 30, 2021.

	Р	rincipal Payments of Long-Term Debt
2021	\$	137
2022	\$	559
2023	\$	575
2024	\$	261,646

Senior Secured Credit Facility

The Company has a \$600 million senior secured revolving credit facility, subject to the terms of a Second Amended and Restated Credit Agreement dated as of March 31, 2015, as amended to date (as amended and modified the "Amended Credit Agreement"), that becomes due and payable in full upon maturity on September 27, 2024. The Amended Credit Agreement provides the option to increase the revolving credit facility or establish term loan facilities in an aggregate amount of up to \$150 million, subject to customary conditions and the approval of any lender whose commitment would be increased, resulting in a maximum available principal amount under the Amended Credit Agreement of \$750 million. The initial borrowings under the Amended Credit Agreement were used to refinance borrowings outstanding under a prior credit agreement, and future borrowings under the Amended Credit Agreement may be used for working capital, capital expenditures, acquisitions of businesses, share repurchases, and general corporate purposes.

Fees and interest on borrowings vary based on our Consolidated Leverage Ratio (as defined in the Amended Credit Agreement). At our option, borrowings under the Amended Credit Agreement will bear interest at one, two, three or six-month LIBOR or an alternate base rate, in each case plus the applicable margin. The applicable margin will fluctuate between 1.125% per annum and 1.875% per annum, in the case of LIBOR borrowings, or between 0.125% per annum and 0.875% per annum, in the case of base rate loans, based upon our Consolidated Leverage Ratio at such time.

Amounts borrowed under the Amended Credit Agreement may be prepaid at any time without premium or penalty. We are required to prepay the amounts outstanding under the Amended Credit Agreement in certain circumstances, including upon an Event of Default (as defined in the Amended Credit Agreement). In addition, we have the right to permanently reduce or terminate the unused portion of the commitments provided under the Amended Credit Agreement at any time.

The loans and obligations under the Amended Credit Agreement are secured pursuant to a Second Amended and Restated Security Agreement and a Second Amended and Restated Pledge Agreement (the "Pledge Agreement") with Bank of America, N.A. as collateral agent, pursuant to which the Company and the subsidiary guarantors grant Bank of America, N.A., for the ratable benefit of the lenders under the Amended Credit Agreement, a first-priority lien, subject to permitted liens, on substantially all of the personal property assets of the Company and the subsidiary guarantors, and a pledge of 100% of the stock or other equity interests in all domestic subsidiaries and 65% of the stock or other equity interests in each "material first-tier foreign subsidiary" (as defined in the Pledge Agreement).

The Amended Credit Agreement contains usual and customary representations and warranties; affirmative and negative covenants, which include limitations on liens, investments, additional indebtedness, and restricted payments; and two quarterly financial covenants as follows: (i) a maximum Consolidated Leverage Ratio (defined as the ratio of debt to consolidated EBITDA) of 3.75 to 1.00; however the maximum permitted Consolidated Leverage Ratio will increase to 4.00 to 1.00 upon the occurrence of certain transactions, and (ii) a minimum Consolidated Interest Coverage Ratio (defined as the ratio of consolidated EBITDA to interest) of 3.50 to 1.00. Consolidated EBITDA for purposes of the financial covenants is calculated on a continuing operations basis and includes adjustments to add back non-cash goodwill impairment charges, share-based compensation costs, certain non-cash restructuring charges, pro forma historical EBITDA for businesses

acquired, and other specified items in accordance with the Amended Credit Agreement. For purposes of the Consolidated Leverage Ratio, total debt is on a gross basis and is not netted against our cash balances. At September 30, 2021, we were in compliance with these financial covenants with a Consolidated Leverage Ratio of 2.73 to 1.00 and a Consolidated Interest Coverage Ratio of 13.99 to 1.00.

Borrowings outstanding under the Amended Credit Agreement at September 30, 2021 totaled \$260.0 million. These borrowings carried a weighted average interest rate of 2.7%, including the effect of the interest rate swaps described in Note 9 "Derivative Instruments and Hedging Activity." Borrowings outstanding under the Amended Credit Agreement at December 31, 2020 were \$200.0 million and carried a weighted average interest rate of 2.5%, including the effect of the interest rate swaps. The borrowing capacity under the revolving credit facility is reduced by any outstanding borrowings under the revolving credit facility and outstanding letters of credit. At September 30, 2021, we had outstanding letters of credit totaling \$0.7 million, which are used as security deposits for our office facilities. As of September 30, 2021, the unused borrowing capacity under the revolving credit facility was \$339.3 million.

Promissory Note due 2024

On June 30, 2017, in conjunction with our purchase of an aircraft related to the acquisition of Innosight, we assumed, from the sellers of the aircraft, a promissory note with an outstanding principal balance of \$5.1 million. The principal balance of the promissory note is subject to scheduled monthly principal payments until the maturity date of March 1, 2024, at which time a final payment of \$1.5 million, plus any accrued and unpaid interest, will be due. Under the terms of the promissory note, we pay interest on the outstanding principal amount at a rate of one month LIBOR plus 1.97% per annum. The obligations under the promissory note are secured pursuant to a Loan and Aircraft Security Agreement with Banc of America Leasing & Capital, LLC, which grants the lender a first priority security interest in the aircraft. At September 30, 2021, the outstanding principal amount of the promissory note was \$2.9 million, and the aircraft had a carrying amount of \$4.4 million.

8. Restructuring Charges

Restructuring charges for the three and nine months ended September 30, 2021 were \$1.7 million and \$3.2 million, respectively. The \$1.7 million of restructuring charges recognized in the third quarter of 2021 consisted of \$0.7 million of third-party transaction expenses related to the evaluation of the divestiture of our Life Sciences business within our Business Advisory segment, \$0.5 million of rent and related expenses, net of sublease income, for previously vacated office spaces, and \$0.5 million of employee-related expenses. Of the \$3.2 million restructuring charge incurred in the first nine months of 2021, \$1.8 million related to rent and related expenses, net of sublease income, and accelerated depreciation on furniture and fixtures for vacated office spaces; \$0.9 million related to third-party transaction expenses related to the evaluation of the divestiture of our Life Sciences business within our Business Advisory segment; and \$0.5 million related to the evaluation of the divestiture of our Life Sciences business within our Business Advisory segment; and \$0.5 million related to the employee-related expenses recognized in the third quarter of 2021.

Restructuring charges for the three and nine months ended September 30, 2020 were \$0.1 million and \$1.8 million, respectively. The \$0.1 million charge recognized in the third quarter of 2020 primarily related to rent and related expenses, net of sublease income, for vacated office spaces. Restructuring charges recognized in the first nine months of 2020 include a \$1.2 million accrual for the termination of a third-party advisor agreement, \$0.3 million related to workforce reductions to better align resources with market demand, \$0.2 million related to rent and related expenses, net of sublease income, for vacated office spaces, and \$0.1 million related to workforce reductions in our corporate operations.

In the fourth quarter of 2020, we announced a restructuring plan to reduce operating costs to address the impact of the COVID-19 pandemic on our business. The restructuring plan, which was substantially complete in the fourth quarter of 2020, provided for a reduction in certain leased office spaces and a reduction in workforce.



The table below sets forth the changes in the carrying amount of our restructuring charge liability by restructuring type for the nine months ended September 30, 2021.

	Employee Costs	Office Space Reductions	Other	Total
Balance as of December 31, 2020	\$ 2,447	\$ 84	\$ 893	\$ 3,424
Additions	504	—	927	1,431
Payments	(2,438)	(84)	(707)	(3,229)
Adjustments	(13)	—	—	(13)
Balance as of September 30, 2021	\$ 500	\$ —	\$ 1,113	\$ 1,613

The restructuring charge liability related to employee costs at September 30, 2021 is expected to be paid in the next 12 months and is included as a component of accrued payroll and related benefits. The employee related payments made in the first nine months of 2021 primarily related to the fourth quarter 2020 restructuring plan. Of the \$1.1 million other restructuring charge liability at September 30, 2021,\$0.6 million is related to the divestiture of our Life Sciences business within our Business Advisory segment and is expected to be paid over the next 12 months and the remaining \$0.5 million is related to the termination of a third-party advisor agreement expected to be paid over the next 16 months. The other restructuring charge liabilities are included as a component of accrued expenses and other current liabilities and deferred compensation and other liabilities.

9. Derivative Instruments and Hedging Activity

On June 22, 2017, we entered into a forward interest rate swap agreement effective August 31, 2017 and ending August 31, 2022, with a notional amount of \$50.0 million. We entered into this derivative instrument to hedge against the interest rate risks of our variable-rate borrowings. Under the terms of the interest rate swap agreement, we receive from the counterparty interest on the notional amount based on one month LIBOR and we pay to the counterparty a fixed rate of 1.900%.

On January 30, 2020, we entered into a forward interest rate swap agreement effective December 31, 2019 and ending December 31, 2024, with a notional amount of \$50.0 million. We entered into this derivative instrument to further hedge against the interest rate risks of our variable-rate borrowings. Under the terms of the interest rate swap agreement, we receive from the counterparty interest on the notional amount based on one month LIBOR and we pay to the counterparty a fixed rate of 1.500%.

On March 16, 2020, we entered into a forward interest rate swap agreement effective February 28, 2020 and ending February 28, 2025, with a notional amount of \$100.0 million. We entered into this derivative instrument to further hedge against the interest rate risks of our variablerate borrowings. Under the terms of the interest rate swap agreement, we receive from the counterparty interest on the notional amount based on one month LIBOR and we pay to the counterparty a fixed rate of 0.885%.

We recognize all derivative instruments as either assets or liabilities at fair value on the balance sheet. We have designated these derivative instruments as cash flow hedges. Therefore, changes in the fair value of the derivative instruments are recorded to other comprehensive income ("OCI") to the extent effective and reclassified into interest expense upon settlement. As of September 30, 2021, it was anticipated that \$1.7 million of the losses, net of tax, currently recorded in accumulated other comprehensive income will be reclassified into earnings within the next 12 months.

The table below sets forth additional information relating to the interest rate swaps designated as a cash flow hedging instrument as of September 30, 2021 and December 31, 2020.

	Fair	Value (Derivativ	e As	set and Liability)
Balance Sheet Location	Sept	tember 30, 2021		December 31, 2020
Accrued expenses and other current liabilities	\$	2,051	\$	2,100
Deferred compensation and other liabilities	\$	660	\$	3,297

All of our derivative instruments are transacted under the International Swaps and Derivatives Association (ISDA) master agreements. These agreements permit the net settlement of amounts owed in the event of default and certain other termination events. Although netting is permitted, it is our policy to record all derivative assets and liabilities on a gross basis on our consolidated balance sheet.

We do not use derivative instruments for trading or other speculative purposes. Refer to Note 11 "Other Comprehensive Income (Loss)" for additional information on our derivative instruments.

10. Fair Value of Financial Instruments

Certain of our assets and liabilities are measured at fair value. Fair value is defined as the price that would be received to sell an asset or the price that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a fair value hierarchy for inputs used in measuring fair value and requires companies to maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy consists of three levels based on the objectivity of the inputs as follows:

- Level 1 Inputs Quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
- Level 2 Inputs Quoted prices in active markets for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3 Inputs Unobservable inputs for the asset or liability, and include situations in which there is little, if any, market activity for the asset or liability.

The table below sets forth our fair value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020.

	Lev	/el 1	Level 2			Level 3	Total
September 30, 2021							
Assets:							
Convertible debt investment	\$	—	\$	—	\$	61,549	\$ 61,549
Deferred compensation assets		—		37,195		—	37,195
Total assets	\$		\$	37,195	\$	61,549	\$ 98,744
Liabilities:							
Interest rate swaps	\$	—	\$	2,711	\$	_	\$ 2,711
Contingent consideration for business acquisition		—		—		1,868	1,868
Total liabilities	\$	_	\$	2,711	\$	1,868	\$ 4,579
December 31, 2020							
Assets:							
Convertible debt investment	\$	—	\$		\$	64,364	\$ 64,364
Deferred compensation assets		—		34,056		—	34,056
Total assets	\$	_	\$	34,056	\$	64,364	\$ 98,420
Liabilities:							
Interest rate swaps	\$	—	\$	5,397	\$	—	\$ 5,397
Contingent consideration for business acquisition				—		1,770	1,770
Total liabilities	\$	_	\$	5,397	\$	1,770	\$ 7,167

Interest rate swaps: The fair values of our interest rate swaps were derived using estimates to settle the interest rate swap agreements, which are based on the net present value of expected future cash flows on each leg of the swaps utilizing market-based inputs and a discount rate reflecting the risks involved. Refer to Note 9 "Derivative Instruments and Hedging Activity" for additional information on our interest rate swaps.

Convertible debt investment: In 2014 and 2015, we invested \$27.9 million, in the form of zero coupon convertible debt (the "initial convertible notes"), in Shorelight Holdings, LLC ("Shorelight"), the parent company of Shorelight, a U.S.-based company that partners with leading nonprofit universities to increase access to and retention of international students, boost institutional growth, and enhance an institution's global footprint. In the first quarter of 2020, we invested an additional \$13.0 million, in the form of 1.69% convertible debt with a senior liquidation preference to the initial convertible notes (the "additional convertible note") and amended our initial convertible notes to extend the maturity date to January 17, 2024, which coincides with the maturity date of the additional convertible note.

To determine the appropriate accounting treatment for our investment, we performed a variable interest entity ("VIE") analysis and concluded that Shorelight does not meet the definition of a VIE. We also reviewed the characteristics of our investment to confirm that the convertible

notes are not in-substance common stock that would warrant equity method accounting. After we reviewed all of the terms of the investment, we concluded the appropriate accounting treatment to be that of an available-for-sale debt security.

The investment is carried at fair value with unrealized holding gains and losses excluded from earnings and reported in other comprehensive income. We estimate the fair value of our investment using a scenario-based approach in the form of a hybrid analysis that consists of a Monte Carlo simulation model and an expected return analysis. The conclusion of value for our investment is based on the probability-weighted assessment of both scenarios. The hybrid analysis utilizes certain assumptions including the assumed holding period through the maturity date of January 17, 2024; the applicable waterfall distribution at the end of the expected holding period based on the rights and privileges of the various instruments; cash flow projections discounted at the risk-adjusted rate of 22.5% and 24.0% as of September 30, 2021 and December 31, 2020, respectively; and the concluded equity volatility of 45.0% as of both September 30, 2021 and December 31, 2020, respectively; and the concluded equity volatility of 45.0% as of both September 30, 2021 and December 31, 2020, new of alternative estimates and assumptions could increase or decrease the estimated fair value of the investment, which would result in different impacts to our consolidated balance sheet and comprehensive income. Actual results may differ from our estimates. The fair value of the convertible debt investment is recorded in long-term investments on our consolidated balance sheets.

The table below sets forth the changes in the balance of the convertible debt investment for the nine months ended September 30, 2021.

	Convertible	Debt Investment
Balance as of December 31, 2020	\$	64,364
Change in fair value of convertible debt investment		(2,815)
Balance as of September 30, 2021	\$	61,549

Deferred compensation assets: We have a non-qualified deferred compensation plan (the "Plan") for the members of our board of directors and a select group of our employees. The deferred compensation liability is funded by the Plan assets, which consist of life insurance policies maintained within a trust. The cash surrender value of the life insurance policies approximates fair value and is based on third-party broker statements which provide the fair value of the life insurance policies' underlying investments, which are Level 2 inputs. The cash surrender value of the life insurance policies is invested primarily in mutual funds. The Plan assets are included in other non-current assets on our consolidated balance sheets. Realized and unrealized gains (losses) from the deferred compensation assets are recorded to other income (expense), net in our consolidated statements of operations.

Contingent consideration for business acquisition: We estimate the fair value of acquisition-related contingent consideration using either a probability-weighted assessment of the specific financial performance targets being measured or a Monte Carlo simulation model, as appropriate. These fair value measurements are based on significant inputs not observable in the market and thus represent Level 3 inputs. The significant unobservable inputs used in the fair value measurements of our contingent consideration are our measures of the estimated payouts based on internally generated financial projections on a probability-weighted basis and a discount rate which typically reflects a risk-free rate, and was 2.39% and 2.41% as of September 30, 2021 and December 31, 2020, respectively. The fair value of the contingent consideration is reassessed quarterly based on assumptions used in our latest projections and input provided by practice leaders and management. Any change in the fair value estimate is recorded in our consolidated statement of operations for that period. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of our contingent consideration liability, which would result in different impacts to our consolidated balance sheets and consolidated statements of operations. Actual results may differ from our estimates.

The table below sets forth the changes in the balance of the contingent consideration for business acquisitions for the nine months ended September 30, 2021.

	Consideration for Acquisitions
Balance as of December 31, 2020	\$ 1,770
Change in fair value of contingent consideration for business acquisition	98
Balance as of September 30, 2021	\$ 1,868

Financial assets and liabilities not recorded at fair value are as follows:

Preferred Stock Investment

In the fourth quarter of 2019, we invested \$5.0 million, in the form of preferred stock, in Medically Home Group, Inc. ("Medically Home"), a healthcare technology-enabled services company. To determine the appropriate accounting treatment for our investment, we performed a

VIE analysis and concluded that Medically Home does not meet the definition of a VIE. We also reviewed the characteristics of our investment to confirm that the preferred stock is not in-substance common stock that would warrant equity method accounting. After we reviewed all of the terms of the investment, we concluded the appropriate accounting treatment for our investment in Medically Home to be that of an equity security with no readily determinable fair value. We elected to apply the measurement alternative at the time of the purchase and will continue to do so until the investment does not qualify to be so measured. Under the measurement alternative, the investment is carried at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment in Medically Home. On a quarterly basis, we review the information available to determine whether an orderly and observable transaction for the same or similar equity instrument occurred, and remeasure the fair value of the preferred stock using such identified transactions, with changes in the fair value recorded in consolidated statement of operations. During the nine months ended September 30, 2021, there has been no impairment, nor any observable price change related to our investment. As of September 30, 2021, the carrying amount of our preferred stock investment was \$6.7 million.

Senior Secured Credit Facility

The carrying value of our borrowings outstanding under our senior secured credit facility is stated at cost. Our carrying value approximates fair value, using Level 2 inputs, as the senior secured credit facility bears interest at variable rates based on current market rates as set forth in the Amended Credit Agreement. Refer to Note 7 "Financing Arrangements" for additional information on our senior secured credit facility.

Promissory Note due 2024

The carrying value of our promissory note due 2024 is stated at cost. Our carrying value approximates fair value, using Level 2 inputs, as the promissory note bears interest at rates based on current market rates as set forth in the terms of the promissory note. Refer to Note 7 "Financing Arrangements" for additional information on our promissory note due 2024.

Cash and Cash Equivalents and Other Financial Instruments

Cash and cash equivalents are stated at cost, which approximates fair market value. The carrying values of all other financial instruments not described above reasonably approximate fair market value due to the nature of the financial instruments and the short-term maturity of these items.

11. Other Comprehensive Income (Loss)

The table below sets forth the components of other comprehensive income (loss), net of tax, for the three and nine months ended September 30, 2021 and 2020.

	Three Months Ended September 30, 2021						Three Months Ended September 30, 2020					
	 Before Taxes				Net of Taxes		Before Taxes	Tax (Expense) Benefit			Net of Taxes	
Other comprehensive income (loss):												
Foreign currency translation adjustments	\$ (246)	\$	—	\$	(246)	\$	381	\$	—	\$	381	
Unrealized gain (loss) on investment	\$ 1,577	\$	(419)	\$	1,158	\$	6,598	\$	(1,713)	\$	4,885	
Unrealized gain (loss) on cash flow hedges:												
Change in fair value	\$ (192)	\$	47	\$	(145)	\$	(903)	\$	234	\$	(669)	
Reclassification adjustments into earnings	613		(159)		454		576		(150)		426	
Net unrealized gain (loss)	\$ 421	\$	(112)	\$	309	\$	(327)	\$	84	\$	(243)	
Other comprehensive income (loss)	\$ 1,752	\$	(531)	\$	1,221	\$	6,652	\$	(1,629)	\$	5,023	



	Nine Months Ended September 30, 2021							Nine Months Ended September 30, 2020					
	Before Taxes		Tax (Expense) Benefit			Net of Taxes		Before Taxes	Tax (Expense) Benefit			Net of Taxes	
Other comprehensive income (loss):													
Foreign currency translation adjustments	\$	236	\$	—	\$	236	\$	(294)	\$		\$	(294)	
Unrealized gain (loss) on investment	\$	(2,815)	\$	747	\$	(2,068)	\$	(1,420)	\$	369	\$	(1,051)	
Unrealized gain (loss) on cash flow hedges:													
Change in fair value	\$	692	\$	(212)	\$	480	\$	(5,815)	\$	1,510	\$	(4,305)	
Reclassification adjustments into earnings		1,994		(518)		1,476		909		(237)		672	
Net unrealized gain (loss)	\$	2,686	\$	(730)	\$	1,956	\$	(4,906)	\$	1,273	\$	(3,633)	
Other comprehensive income (loss)	\$	107	\$	17	\$	124	\$	(6,620)	\$	1,642	\$	(4,978)	

The before tax amounts reclassified from accumulated other comprehensive income related to our cash flow hedges are recorded to interest expense, net of interest income.

Accumulated other comprehensive income, net of tax, includes the following components:

	Foreign Currency Translation		Available-for-Sale Investment	Cash Flow Hedges	Total
Balance, December 31, 2020	\$ (218	\$) \$	5 17,205	\$ (3,926)	\$ 13,061
Current period change	236	5	(2,068)	1,956	124
Balance, September 30, 2021	\$ 18	3 \$	5 15,137	\$ (1,970)	\$ 13,185

12. Income Taxes

For the three months ended September 30, 2021, our effective tax rate was 12.5% as we recognized income tax expense from continuing operations of \$2.0 million on income from continuing operations of \$15.7 million. The effective tax rate of 12.5% was more favorable than the statutory rate, inclusive of state income taxes, of 26.6%, primarily due to a discrete tax benefit for U.S. federal return to provision adjustments related to the 2020 corporate income tax return.

For the three months ended September 30, 2020, our effective tax rate was 17.7% as we recognized income tax expense from continuing operations of \$2.4 million on income from continuing operations of \$13.5 million. The effective tax rate of 17.7% was more favorable than the statutory rate, inclusive of state income taxes, of 26.0%, primarily due to the year-to-date pre-tax losses and the impact during the quarter of certain nondeductible expense items, including the nondeductible portion of the goodwill impairment charges, based on the attribution of those expenses to the quarter in accordance with the allocation of income tax expense on a year-to-date basis. The effective tax rate also reflected the positive impact of certain federal tax credits.

For the nine months ended September 30, 2021, our effective tax rate was 17.9% as we recognized income tax expense from continuing operations of \$7.0 million on income from continuing operations of \$38.9 million. The effective tax rate of 17.9% was more favorable than the statutory rate, inclusive of state income taxes, of 26.6% primarily due to the discrete tax benefit during the third quarter of 2021 for U.S. federal return to provision adjustment related to the 2020 corporate income tax return. The effective tax rate also reflected the positive impact of certain federal tax credits and a discrete tax benefit recognized during the second quarter of 2021 related to electing the Global Intangible Low-Taxed Income ("GILTI") high-tax exclusion retroactively for the 2018 tax year. On July 20, 2020, the U.S. Treasury issued and enacted final regulations related to GILTI that allow certain U.S. taxpayers to elect to exclude foreign income that is subject to a high effective tax rate from their GILTI inclusions. The GILTI high-tax exclusion is an annual election and is retroactively available. These favorable items were partially offset by certain nondeductible business expenses.

For the nine months ended September 30, 2020, our effective tax rate was 23.5% as we recognized an income tax benefit from continuing operations of \$5.4 million on a loss from continuing operations of \$23.0 million. The effective tax rate of 23.5% was less favorable than the statutory rate, inclusive of state income taxes, of 26.0%, primarily due to certain nondeductible business expenses and the nondeductible portion of the goodwill impairment charges recorded during the first quarter of 2020. These unfavorable items were partially offset by a discrete tax benefit for share-based compensation awards that vested primarily during the first quarter, the positive impact of certain federal

tax credits and the discrete tax benefit for the remeasurement of a portion of our income tax receivable as a result of the enactment of the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") in the first quarter of 2020.

The CARES Act, which was signed into law on March 27, 2020, is an approximately \$2 trillion emergency economic stimulus package in response to the COVID-19 outbreak, which among other items, includes income tax provisions relating to net operating loss carryback periods and technical corrections to tax depreciation methods for qualified improvement property. In the first nine months of 2020, as a result of the CARES Act, we recognized a \$0.8 million tax benefit related to the remeasurement of a portion of our income tax receivable due to the ability to apply the federal net operating loss incurred in 2018 to prior year income for a refund at the higher tax rate in the carryback period. As a result of electing the retroactive GILTI high-tax exclusion in the second quarter of 2021, we recognized a \$1.0 million tax benefit of which \$0.4 million related to carrying back our increased 2018 federal net operating loss to prior year income for a refund at the higher, prior year tax rate. During the third quarter of 2021, we recognized an additional tax benefit of \$2.0 million, primarily related to the U.S. federal return to provision adjustments for carrying back our increased 2020 federal net operating loss to prior year income for a refund at the higher, prior year tax rate.

13. Commitments, Contingencies and Guarantees

Litigation

Oaktree

On November 9, 2018, Huron Consulting Services LLC, a wholly owned subsidiary of Huron, was engaged by Oaktree Medical Centre LLC, a management services organization ("Oaktree"), to perform interim management and financial advisory services. As part of the services, a Huron employee was appointed by Oaktree's board of directors to serve as Chief Restructuring Officer of Oaktree (the "CRO"). The engagement letter through which Oaktree retained Huron's services (the "Engagement Letter") states that all disputes or claims arising thereunder are subject to binding arbitration, disclaims special, consequential, incidental and exemplary damages and losses and caps liability to the fees paid for the portion of the engagement giving rise to any liability. On September 19, 2019, Oaktree and certain of its affiliates filed for Chapter 7 liquidation in the U.S. Bankruptcy Court for the Western District of North Carolina, with the cases subsequently transferred to the District of South Carolina. As a result of the bankruptcy filing, a Chapter 7 trustee was appointed to oversee the bankruptcy estates, at which time Huron's services for Oaktree concluded.

In April 2021, Trustee's counsel communicated in writing to Huron its intent to pursue various claims against Huron and the CRO, among others, on behalf of the bankruptcy estates related to the services carried out by Huron and the CRO during the engagement.

On September 17, 2021, the Trustee filed a complaint in the Bankruptcy Court for the District of South Carolina against Huron and the CRO, among others (the "Complaint"), alleging breach of fiduciary duty, aiding and abetting a breach of fiduciary duty, negligence, violations of the South Carolina Unfair Trade Practices Act, fraud, civil conspiracy, unjust enrichment, and recovery of avoided transfers under sections 547, 548 and 550 of the Bankruptcy Code. In the Complaint, the Trustee asserts that Huron and the CRO, among others, did not develop and implement a Chapter 11 restructuring plan on a timely basis and that their failure to do so led to significant damages. The Trustee seeks an unspecified amount of monetary damages in the Complaint. We believe the Trustee's allegations with respect to Huron and the CRO are without merit and will vigorously defend ourselves against the allegations raised in the Complaint. Notwithstanding the foregoing, given the inherent risk and uncertainty associated with all litigation, we cannot estimate the potential liability with respect to such allegations at this time.

From time to time, we are involved in legal proceedings and litigation arising in the ordinary course of business. As of the date of this Quarterly Report on Form 10-Q, we are not a party to any litigation or legal proceeding or subject to any claim that, in the current opinion of management, could reasonably be expected to have a material adverse effect on our financial position or results of operations. However, due to the risks and uncertainties inherent in legal proceedings, actual results could differ from current expected results.

Guarantees

Guarantees in the form of letters of credit totaling \$0.7 million and \$1.6 million were outstanding at September 30, 2021 and December 31, 2020, respectively, primarily to support certain office lease obligations.

In connection with certain business acquisitions, we may be required to pay post-closing consideration to the sellers if specific financial performance targets are met over a number of years as specified in the related purchase agreements. As of September 30, 2021 and December 31, 2020, the total estimated fair value of our outstanding contingent consideration liability was \$1.9 million and \$1.8 million, respectively.

To the extent permitted by law, our bylaws and articles of incorporation require that we indemnify our officers and directors against judgments, fines and amounts paid in settlement, including attorneys' fees, incurred in connection with civil or criminal action or proceedings, as it relates to their services to us if such person acted in good faith. Although there is no limit on the amount of indemnification, we may have recourse against our insurance carrier for certain payments made.

14. Segment Information

Segments are defined as components of a company that engage in business activities from which they may earn revenues and incur expenses, and for which separate financial information is available and is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision maker, who is our chief executive officer, manages the business under three operating segments, which are our reportable segments: Healthcare, Business Advisory, and Education.

Healthcare

Our Healthcare segment serves national and regional hospitals, integrated health systems, academic medical centers, community hospitals, and medical groups. Our Healthcare professionals have a depth of expertise in business operations, including financial and operational improvement, care transformation, and revenue cycle managed services; organizational transformation; and digital, technology and analytic solutions. Most healthcare organizations are focused on changing the way care is delivered; establishing a sustainable business model centered around optimal cost structures, reimbursement models and financial strategies; and evolving their digital, technology and analytic capabilities. Our solutions help clients adapt to this rapidly changing healthcare environment to become a more agile, efficient and consumer-centric organization. We use our deep industry expertise to help clients solve a diverse set of business issues, including, but not limited to, optimizing financial and operational performance, improving care delivery and clinical outcomes, increasing physician, patient and employee satisfaction, evolving organizational culture, and maximizing return on technology investments.

Business Advisory

Our Business Advisory segment works with C-suite executives, boards, and business unit and functional leadership across a diverse set of organizations, including healthy, well-capitalized companies to organizations in transition, and across a broad range of industries, including financial services, healthcare, education, energy and utilities, industrials and manufacturing, and the public sector. Our Business Advisory professionals have deep industry, functional and technical expertise that they put forward when delivering our digital, technology and analytics, strategy and innovation and corporate finance and restructuring services. In today's disruptive environment, organizations must reimagine their historical strategies and financial and operating models to sustain and advance their competitive advantage. Organizations also recognize the need to adopt technologies, automation and analytics to improve their operations and compete in a rapidly changing environment. Our experts help organizations across industries with a variety of business challenges, including, but not limited to, embedding technology and analytics throughout their internal and customer-facing operations, developing insights into the needs of tomorrow's customers in order to evolve their enterprise and business unit strategies, bringing new products to market, and managing through stressed and distressed situations to create a viable path forward for stakeholders.

- Education

Our Education segment serves public and private colleges and universities, academic medical centers, research institutes and other not-for-profit organizations. Our Education professionals have a depth of expertise in strategy and innovation; business operations, including the research enterprise and student lifecycle; digital, technology and analytic solutions; and organizational transformation. Our Education segment clients are increasingly faced with financial and/or demographic challenges as well as increased competition. To remain competitive, organizations must challenge traditional operating and financial models and reimagine strategic, operational and research-centered opportunities that advance their mission while strengthening their business models. We collaborate with clients to address these challenges and ensure they have a sustainable future. We combine our deep industry, functional and technical expertise to help clients solve their most pressing challenges, including, but not limited to, transforming business operations with technology; strengthening research strategies and support services; evolving their organizational strategy; optimizing financial and operational performance; and enhancing the student lifecycle.

Segment operating income consists of the revenues generated by a segment, less the direct costs of revenue and selling, general and administrative expenses that are incurred directly by the segment. Unallocated corporate costs include costs related to administrative functions that are performed in a centralized manner that are not attributable to a particular segment. These administrative function costs

include costs for corporate office support, certain office facility costs, costs relating to accounting and finance, human resources, legal, marketing, information technology, and company-wide business development functions, as well as costs related to overall corporate management.

The table below sets forth information about our operating segments for the three and nine months ended September 30, 2021 and 2020, along with the items necessary to reconcile the segment information to the totals reported in the accompanying consolidated financial statements.

	Three Mo Septe				Nine Mo Septe			
	 2021		2020		2021		2020	
Healthcare:				_				
Revenues	\$ 92,845	\$	87,406	\$	273,924	\$	268,340	
Operating income	\$ 30,255	\$	25,610	\$	78,363	\$	70,831	
Segment operating income as a percentage of segment revenues	32.6 %	, D	29.3 %	, D	28.6 %	б	26.4 %	
Business Advisory:								
Revenues	\$ 69,966	\$	66,048	\$	213,741	\$	201,423	
Operating income	\$ 9,892	\$	10,780	\$	37,284	\$	37,306	
Segment operating income as a percentage of segment revenues	14.1 %	ó	16.3 %	, D	17.4 %	6	18.5 %	
Education:								
Revenues	\$ 61,196	\$	51,850	\$	169,681	\$	176,017	
Operating income	\$ 14,788	\$	12,548	\$	37,211	\$	41,792	
Segment operating income as a percentage of segment revenues	24.2 %	, D	24.2 %	, D	21.9 %	б	23.7 %	
Total Company:								
Revenues	\$ 224,007	\$	205,304	\$	657,346	\$	645,780	
Reimbursable expenses	3,690		2,860		8,876		25,133	
Total revenues and reimbursable expenses	\$ 227,697	\$	208,164	\$	666,222	\$	670,913	
Segment operating income	\$ 54,935	\$	48,938	\$	152,858	\$	149,929	
Items not allocated at the segment level:	- ,		-,		- ,		- ,	
Other operating expenses	31,374		29,042		94,536		87,826	
Litigation and other losses (gains)	56				98		(150)	
Depreciation and amortization	5,199		6,197		15,549		18,635	
Goodwill impairment charges ¹			_		_		59,816	
Other expense, net	2,611		224		3,788		6,829	
Income (loss) from continuing operations before taxes	\$ 15,695	\$	13,475	\$	38,887	\$	(23,027)	

(1) The non-cash goodwill impairment charges are not allocated at the segment level because the underlying goodwill asset is reflective of our corporate investment in the segments. We do not include the impact of goodwill impairment charges in our evaluation of segment performance.



The following table illustrates the disaggregation of revenues by billing arrangements, employee types, and timing of revenue recognition, including a reconciliation of the disaggregated revenues to revenues from our three operating segments for the three and nine months ended September 30, 2021 and 2020.

In conjunction with our continuous evaluation of the appropriate level of disaggregation of revenues as our business evolves and in consideration of a group hire of approximately 300 employees in our Healthcare Managed Services solution within our Healthcare segment in the second quarter of 2021, we began assessing our operating performance by the following three employee types: billable consultants, full-time equivalents, and Healthcare Managed Services employees. The disaggregation of revenues by employee type previously reported for the three and nine months ended September 30, 2020 was revised below to reflect this change. This change has no impact on our consolidated total revenues or total revenues by segment.

	Three Months Ended September 30, 2021							
Fixed-fee \$ 56,836 \$ 30,783 \$ 14,985 \$ 102,60	Education Total							
Time and summer 00 001 01 01 01 01	\$ 14,985 \$ 102,604							
Time and expense 17,823 35,261 38,831 91,91	38,831 91,915							
Performance-based 12,689 1,596 — 14,28	— 14,285							
Software support, maintenance and subscriptions5,4972,3267,38015,20	7,380 15,203							
Total \$ 92,845 \$ 69,966 \$ 61,196 \$ 224,00	\$ 61,196 \$ 224,007							
Employee Type ⁽¹⁾								
Revenue generated by billable consultants \$ 59,502 \$ 64,469 \$ 51,237 \$ 175,20	\$ 51,237 \$ 175,208							
Revenue generated by full-time equivalents19,7315,4979,95935,18	9,959 35,187							
Revenue generated by Healthcare Managed Services employees 13,612 — — 13,61	— 13,612							
Total \$ 92,845 \$ 69,966 \$ 61,196 \$ 224,00	\$ 61,196 \$ 224,007							
Timing of Revenue Recognition								
Revenue recognized over time \$ 91,800 \$ 69,966 \$ 60,921 \$ 222,68	\$ 60,921 \$ 222,687							
Revenue recognized at a point in time 1,045 — 275 1,32	275 1,320							
Total \$ 92,845 \$ 69,966 \$ 61,196 \$ 224,00	\$ 61,196 \$ 224,007							

	Nine Months Ended September 30, 2021							
	Healthcare		_	Business Advisory	Е	ducation		Total
Billing Arrangements								
Fixed-fee	\$	160,226	\$	92,014	\$	48,130	\$	300,370
Time and expense		47,237		108,882		100,654		256,773
Performance-based		50,419		6,522		—		56,941
Software support, maintenance and subscriptions		16,042		6,323		20,897		43,262
Total	\$	273,924	\$	213,741	\$	169,681	\$	657,346
Employee Type ⁽¹⁾								
Revenue generated by billable consultants	\$	178,057	\$	200,367	\$	143,056	\$	521,480
Revenue generated by full-time equivalents		60,458		13,374		26,625		100,457
Revenue generated by Healthcare Managed Services employees		35,409		—		—		35,409
Total	\$	273,924	\$	213,741	\$	169,681	\$	657,346
Timing of Revenue Recognition								
Revenue recognized over time	\$	270,448	\$	213,741	\$	169,406	\$	653,595
Revenue recognized at a point in time		3,476		_		275		3,751
Total	\$	273,924	\$	213,741	\$	169,681	\$	657,346

	Three Months Ended September 30, 2020								
	Healthcare		Business Advisory		Education			Total	
Billing Arrangements									
Fixed-fee	\$	51,491	\$	20,675	\$	10,958	\$	83,124	
Time and expense		14,627		40,511		35,214		90,352	
Performance-based		15,641		3,671		—		19,312	
Software support, maintenance and subscriptions		5,647		1,191		5,678		12,516	
Total	\$	87,406	\$	66,048	\$	51,850	\$	205,304	
Employee Type ⁽¹⁾									
Revenue generated by billable consultants	\$	60,034	\$	62,340	\$	44,234	\$	166,608	
Revenue generated by full-time equivalents		20,949		3,708		7,616		32,273	
Revenue generated by Healthcare Managed Services employees		6,423		_				6,423	
Total	\$	87,406	\$	66,048	\$	51,850	\$	205,304	
Timing of Revenue Recognition									
Revenue recognized over time	\$	86,413	\$	66,048	\$	51,663	\$	204,124	
Revenue recognized at a point in time		993		_		187		1,180	
Total	\$	87,406	\$	66,048	\$	51,850	\$	205,304	

	Nine Months Ended September 30, 2020								
	н	Healthcare		Business Advisory		ducation		Total	
Billing Arrangements									
Fixed-fee	\$	158,079	\$	73,442	\$	35,530	\$	267,051	
Time and expense		43,389		118,364		123,493		285,246	
Performance-based		49,042		5,903		695		55,640	
Software support, maintenance and subscriptions		17,830		3,714		16,299		37,843	
Total	\$	268,340	\$	201,423	\$	176,017	\$	645,780	
Employee Type ⁽¹⁾									
Revenue generated by billable consultants	\$	177,149	\$	191,566	\$	150,857	\$	519,572	
Revenue generated by full-time equivalents		69,698		9,857		25,160		104,715	
Revenue generated by Healthcare Managed Services employees		21,493		_				21,493	
Total	\$	268,340	\$	201,423	\$	176,017	\$	645,780	
Timing of Revenue Recognition									
Revenue recognized over time	\$	265,813	\$	201,423	\$	175,715	\$	642,951	
Revenue recognized at a point in time		2,527		_		302		2,829	
Total	\$	268,340	\$	201,423	\$	176,017	\$	645,780	

(1) Billable consultants consist of our consulting professionals who provide consulting services to our clients and are billable to our clients based on the number of hours worked. Full-time equivalent professionals consist of leadership coaches and their support staff within our Culture and Organizational Excellence solution, consultants who work variable schedules as needed by our clients, and full-time employees who provide software support and maintenance services to our clients. Healthcare Managed Services employees manage and provide revenue cycle billing, collections, insurance verification and change integrity services to healthcare clients.

At September 30, 2021 and December 31, 2020, no single client accounted for greater than 10% of our combined balance of receivables from clients, net and unbilled services, net. During the three and nine months ended September 30, 2021 and 2020, no single client generated greater than 10% of our consolidated revenues.

15. Subsequent Event

On November 1, 2021, we completed the divestiture of our Life Sciences business to Oliver Wyman. The Life Sciences business, a reporting unit within the Business Advisory segment, provides commercial and research and development strategy, pricing and market access strategy solutions to customers in the life sciences industries. For the three and nine months ended September 30, 2021, Life Sciences revenues were \$5.1 million and \$14.8 million, respectively. The Life Sciences business is not significant to our consolidated financial statements and does not qualify as a discontinued operation for reporting under GAAP.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

In this Quarterly Report on Form 10-Q, unless the context otherwise requires, the terms "Huron," "Company," "we," "us" and "our" refer to Huron Consulting Group Inc. and its subsidiaries.

Statements in this Quarterly Report on Form 10-O that are not historical in nature, including those concerning the Company's current expectations about its future results, are "forward-looking" statements as defined in Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by words such as "may," "should," "expects," "provides," "anticipates," "assumes," "can," "will," "meets," "could," "likely," "intends," "might," "predicts," "seeks," "would," "believes," "estimates," "plans," "continues," "guidance," or "outlook," or similar expressions. These forward-looking statements reflect our current expectations about our future requirements and needs, results, levels of activity, performance, or achievements. Some of the factors that could cause actual results to differ materially from the forward-looking statements contained herein include, without limitation: the impact of the COVID-19 pandemic on the economy, our clients and client demand for our services, and our ability to sell and provide services, including the measures taken by governmental authorities and businesses in response to the pandemic, which may cause or contribute to other risks and uncertainties that we face; failure to achieve expected utilization rates, billing rates, and the number of revenue-generating professionals; inability to expand or adjust our service offerings in response to market demands; our dependence on renewal of client-based services; dependence on new business and retention of current clients and gualified personnel; failure to maintain third-party provider relationships and strategic alliances; inability to license technology to and from third parties; the impairment of goodwill; various factors related to income and other taxes; difficulties in successfully integrating the businesses we acquire and achieving expected benefits from such acquisitions; risks relating to privacy, information security, and related laws and standards; and a general downturn in market conditions. These forward-looking statements involve known and unknown risks, uncertainties, and other factors, including, among others, those described under Item 1A. "Risk Factors," in our Annual Report on Form 10-K for the year ended December 31, 2020 that may cause actual results, levels of activity, performance or achievements to be materially different from any anticipated results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. We disclaim any obligation to update or revise any forward-looking statements as a result of new information or future events, or for any other reason.

OVERVIEW

Our Business

Huron is a global consultancy that collaborates with clients to drive strategic growth, ignite innovation and navigate constant change. Through a combination of strategy, expertise and creativity, we help clients accelerate operational, digital and cultural transformation, enabling the change they need to own their future. By embracing diverse perspectives, encouraging new ideas and challenging the status quo, we create sustainable results for the organizations we serve.

We provide professional services through three operating segments: Healthcare, Business Advisory, and Education.

Healthcare

Our Healthcare segment serves national and regional hospitals, integrated health systems, academic medical centers, community hospitals, and medical groups. Our Healthcare professionals have a depth of expertise in business operations, including financial and operational improvement, care transformation, and revenue cycle managed services; organizational transformation; and digital, technology and analytic solutions. Most healthcare organizations are focused on changing the way care is delivered; establishing a sustainable business model centered around optimal cost structures, reimbursement models and financial strategies; and evolving their digital, technology and analytic capabilities. Our solutions help clients adapt to this rapidly changing healthcare environment to become a more agile, efficient and consumer-centric organization. We use our deep industry expertise to help clients solve a diverse set of business issues, including, but not limited to, optimizing financial and operational performance, improving care delivery and clinical outcomes, increasing physician, patient and employee satisfaction, evolving organizational culture, and maximizing return on technology investments.

Business Advisory

Our Business Advisory segment works with C-suite executives, boards, and business unit and functional leadership across a diverse set of organizations, including healthy, well-capitalized companies to organizations in transition, and across a broad range of industries, including financial services, healthcare, education, energy and utilities, industrials and manufacturing, and the public sector. Our Business Advisory professionals have deep industry, functional and technical expertise that they put forward when delivering our digital, technology and analytics, strategy and innovation and corporate finance and restructuring services. In today's disruptive environment, organizations must reimagine their historical strategies and financial and operating models to sustain and advance their competitive advantage. Organizations also recognize the need to adopt technologies, automation and analytics to improve their operations and compete in a rapidly changing environment. Our experts help organizations across industries with a variety of business challenges, including, but not limited to, embedding technology and analytics throughout their internal and customer-facing operations, developing insights into the needs of tomorrow's customers in order to evolve their enterprise and business unit strategies, bringing new products to market, and managing through stressed and distressed situations to create a viable path forward for stakeholders.

• Education

Our Education segment serves public and private colleges and universities, academic medical centers, research institutes and other not-for-profit organizations. Our Education professionals have a depth of expertise in strategy and innovation; business operations, including the research enterprise and student lifecycle; digital, technology and analytic solutions; and organizational transformation. Our Education segment clients are increasingly faced with financial and/or demographic challenges as well as increased competition. To remain competitive, organizations must challenge traditional operating and financial models and reimagine strategic, operational and research-centered opportunities that advance their mission while strengthening their business models. We collaborate with clients to address these challenges and ensure they have a sustainable future. We combine our deep industry, functional and technical expertise to help clients solve their most pressing challenges, including, but not limited to, transforming business operations with technology; strengthening research strategies and support services; evolving their organizational strategy; optimizing financial and operational performance; and enhancing the student lifecycle.

Huron is an Oracle partner, a Gold-level consulting partner with Salesforce.com and a Premium Partner with Salesforce.org, a Workday Services and Software Partner, an Amazon Web Services consulting partner, a Silver-level system integrator with Informatica and an SAP Concur implementation partner.

Coronavirus (COVID-19)

The worldwide spread of COVID-19 beginning in 2020 has created significant volatility, uncertainty and disruption to the global economy. This pandemic had an unfavorable impact on aspects of our business, operations, and financial results, and caused us to significantly change the way we operate. Near the end of the first quarter of 2020, we suspended almost all business travel and our employees began working from their homes. While traditionally a majority of the work performed by our revenue-generating professionals occurred at client sites, the nature of the services we provide and enhanced available technology allows our revenue-generating professionals to effectively serve clients in a remote work environment. As federal, state and local government restrictions evolve, we continue to refine our comprehensive plan to return to our offices and client sites with our people's safety and the needs of our clients guiding how we implement our phased transition. As of September 30, 2021, our employees continue to primarily work from their homes; however, most of our offices are open and we are providing our employees the flexibility to choose to work remotely, from our offices, or from client sites as needed and in accordance with recommended public health guidelines.

In each of our operating segments, we are working closely with our clients to support them and their ongoing business needs and provide relevant services to address their needs caused by the COVID-19 pandemic. However, since the beginning of the pandemic, some clients reprioritized and delayed projects which negatively impacted demand for certain offerings, particularly within our Healthcare and Education segments. Conversely, the COVID-19 pandemic strengthened demand for other services we provide, such as our cloud-based technology and analytics solutions within our Business Advisory segment and our restructuring and capital advisory solutions provided to organizations in transition also within our Business Advisory segment.

Beginning in the second quarter of 2021 and continuing through the third quarter of 2021, we saw strengthened demand for services in all of our segments compared to the same prior year period. As a result, total revenues in the first nine months of 2021 increased 1.8% compared to the first nine months of 2020, and total revenues in the third quarter of 2021 increased 9.1% compared to the third quarter of 2020. We expect continued revenue growth in the fourth quarter of 2021 compared to the fourth quarter of 2020.

In order to support our liquidity during the COVID-19 pandemic, we took proactive measures to increase available cash on hand including, but not limited to, borrowing under our senior secured credit facility in the first quarter of 2020 and reducing discretionary operating and capital spending. In the second, third and fourth quarters of 2020, we made repayments on our borrowings to reduce our total debt outstanding to pre-pandemic levels due to our ability to maintain adequate cash flows from operations and improved clarity around access to capital resources. In the first nine months of 2021, we borrowed under our credit facility primarily to fund our annual performance bonus payment. To further support our liquidity during the COVID-19 pandemic, we elected to defer the deposit of our employer portion of social security taxes beginning in April 2020 and through December 31, 2020, as provided for under the CARES Act. These deferred payments, which totaled \$12.2 million, were paid in full in the third quarter of 2021. See the "Liquidity and Capital Resources" section below for additional information on these items.

Enterprise Resource Planning System Implementation

In the fourth quarter of 2019, we began the implementation of a new cloud-based enterprise resource planning ("ERP") system designed to improve the efficiency of our internal finance, human resources, resource planning, and administrative operations. In January 2021, we successfully went live with the new ERP system, and we continue to progress with additional functionality and integrations as scheduled. The implementation progressed on schedule and was not significantly impacted by the COVID-19 pandemic due to the ability of our implementation team to work and collaborate remotely and the enhanced technology and cloud-based nature of our new ERP system. We believe our investment in this new system will position our teams to drive efficiencies and provide more robust management reporting and data analytics to support future growth and the goals and vision of the company.

How We Generate Revenues

A large portion of our revenues is generated by our billable consultants who provide consulting services to our clients and are billable to our clients based on the number of hours worked. A smaller portion of our revenues is generated by our other professionals, also referred to as full-time equivalents, some of whom work variable schedules as needed by our clients. Full-time equivalent professionals consist of our coaches and their support staff from our Culture and Organizational Excellence solution, consultants who work variable schedules as needed by our clients, and our employees who provide software support and maintenance services to our clients. We translate the hours that these other professionals work on client engagements into a full-time equivalent measure that we use to manage our business. Another portion of our revenue is generated by our Healthcare Managed Services employees within our Healthcare segment. Our Healthcare Managed Services employees manage and provide revenue cycle billing, collections, insurance verification and change integrity services to clients. We refer to our billable consultants, full-time equivalents and Healthcare Managed Services employees as revenue-generating professionals.

Revenues generated by our billable consultants are primarily driven by the number of consultants we employ and their utilization rates, as well as the billing rates we charge our clients. Revenues generated by our other professionals, or full-time equivalents, are largely dependent on the number of consultants we employ, their hours worked, and billing rates charged. Revenues generated by our coaches are largely dependent on the number of coaches we employ and the total value, scope, and terms of the consulting contracts under which they provide services, which are primarily fixed-fee contracts. Revenues generated by our Healthcare Managed Services employees are largely dependent on the number of Healthcare Managed Services employees we employ and the total value, scope and terms of the related contracts.

We generate our revenues from providing professional services under four types of billing arrangements: fixed-fee (including software license revenue); time-and-expense; performance-based; and software support, maintenance and subscriptions.

In fixed-fee billing arrangements, we agree to a pre-established fee in exchange for a predetermined set of professional services. We set the fees based on our estimates of the costs and timing for completing the engagements. It is the client's expectation in these engagements that the pre-established fee will not be exceeded except in mutually agreed upon circumstances. We generally recognize revenues under fixed-fee billing arrangements using a proportionate performance approach, which is based on work completed to-date versus our estimates of the total services to be provided under the engagement. Contracts within our Culture and Organizational Excellence solution include fixed-fee partner contracts with multiple performance obligations ("Partner Contracts"), which primarily consist of coaching services, as well as speaking engagements, conferences, publications and software products. Revenues for coaching services and software products are generally recognized on a straight-line basis over the length of the contract. All other revenues under Partner Contracts, including speaking engagements, conferences and publications, are recognized at the time the goods or services are provided.

Fixed-fee arrangements also include software licenses for our revenue cycle management software and research administration and compliance software. Licenses for our revenue cycle management software are sold only as a component of our consulting projects, and the services we provide are essential to the functionality of the software. Therefore, revenues from these software licenses are recognized over the term of the related consulting services contract. License revenue from our research administration and compliance software is generally recognized in the month in which the software is delivered.

Fixed-fee engagements represented 45.8% and 40.5% of our revenues for the three months ended September 30, 2021 and 2020, respectively, and 45.7% and 41.3% of our revenues for the nine months ended September 30, 2021 and 2020, respectively.

Time-and-expense billing arrangements require the client to pay based on the number of hours worked by our revenue-generating professionals at agreed upon rates. Time-and-expense arrangements also include certain speaking engagements, conferences and publications purchased by our clients outside of Partner Contracts within our Culture and Organizational Excellence solution and the portion of our Healthcare Managed Services contracts that are billed under time-and-expense arrangements. We recognize revenues under time-and-expense billing arrangements as the related services or publications are provided. Time-and-expense engagements represented 41.0% and 44.0% of our revenues for the three months ended September 30, 2021 and 2020, respectively, and 39.1% and 44.2% of our revenues for the nine months ended September 30, 2021 and 2020, respectively.

In performance-based fee billing arrangements, fees are tied to the attainment of contractually defined objectives. We enter into performance-based engagements in essentially two forms. First, we generally earn fees that are directly related to the savings formally acknowledged by the client as a result of adopting our recommendations for improving operational and cost effectiveness in the areas we review. Second, we have performance-based engagements in which we earn a success fee when and if certain predefined outcomes occur. Often, performance-based fees supplement our time-and-expense or fixed-fee engagements. We recognize revenues under performance-based billing arrangements by estimating the amount of variable consideration that is probable of being earned and recognizing that estimate over the length of the contract using a proportionate performance approach. Performance-based fee revenues represented 6.4% and 9.4% of our revenues for the three months ended September 30, 2021 and 2020, respectively, and 8.6% and 8.6% of our revenues for the nine months ended September 30, 2021 and 2020, respectively. The level of performance-based fees earned may vary based on our clients' risk sharing preferences and the mix of services we provide.

Clients that have purchased one of our software licenses can pay an annual fee for software support and maintenance. We also generate subscription revenue from our cloud-based analytic tools and solutions. Software support, maintenance and subscription revenues are recognized

ratably over the support or subscription period. These fees are generally billed in advance and included in deferred revenues until recognized. Software support, maintenance and subscription revenues represented 6.8% and 6.1% of our revenues for the three months ended September 30, 2021 and 2020, respectively, and 6.6% and 5.9% of our revenues for the nine months ended September 30, 2021 and 2020, respectively.

Our quarterly results are impacted principally by our billable consultants' utilization rate, the bill rates we charge our clients, and the number of our revenue-generating professionals who are available to work. Our utilization rate can be negatively affected by increased hiring because there is generally a transition period for new professionals that results in a temporary drop in our utilization rate. Our utilization rate can also be affected by seasonal variations in the demand for our services from our clients. For example, during the third and fourth quarters of the year, vacations taken by our clients can result in the deferral of activity on existing and new engagements, which would negatively affect our utilization rate. The number of business work days is also affected by the number of vacation days taken by our consultants and holidays in each quarter. We typically have fewer business work days available in the fourth quarter of the year, which can impact revenues during that period.

Time-and-expense engagements do not provide us with a high degree of predictability as to performance in future periods. Unexpected changes in the demand for our services can result in significant variations in utilization and revenues and present a challenge to optimal hiring and staffing. Moreover, our clients typically retain us on an engagement-by-engagement basis, rather than under long-term recurring contracts. The volume of work performed for any particular client can vary widely from period to period.

Business Strategy, Opportunities and Challenges

Our primary strategy is to meet the needs of our clients by providing a balanced portfolio of service offerings and capabilities so that we can adapt quickly and effectively to emerging opportunities in the marketplace. To achieve this, we continue to hire highly qualified professionals and have entered into select acquisitions of complementary businesses.

To expand our business, we will remain focused on growing our existing relationships and developing new relationships, executing our managing director compensation plan to attract and retain senior practitioners, continuing to promote and provide an integrated approach to service delivery, broadening the scope of our existing services, and acquiring complementary businesses. We will regularly evaluate the performance of our practices to ensure our investments meet these objectives. Furthermore, we intend to enhance our visibility in the marketplace by refining our overarching messaging and value propositions for the organization as well as each practice. We will continue to focus on reaching our client base through clear, concise, and endorsed messages.

RESULTS OF OPERATIONS

The following table sets forth, for the periods indicated, selected segment and consolidated operating results and other operating data.

In conjunction with our continuous evaluation of the appropriate level of disaggregation of revenues as our business evolves and in consideration of a group hire of approximately 300 employees in our Healthcare Managed Services solution within our Healthcare segment in the second quarter of 2021, we began assessing our operating performance by the following three employee types: billable consultants, full-time equivalents, and Healthcare Managed Services employees. The other operating data previously reported for the three and nine months ended September 30, 2020 was revised below to reflect this change. This change has no impact on our consolidated total revenues or total revenues by segment.

Segment and Consolidated Operating Results	Three Months Ended September 30,					Nine Mo Septe		
(in thousands, except per share amounts):		2021		2020		2021		2020
Healthcare:					_		_	
Revenues	\$	92,845	\$	87,406	\$	273,924	\$	268,340
Operating income	\$	30,255	\$	25,610	\$	78,363	\$	70,831
Segment operating income as a percentage of segment revenues	32.6 %		6	29.3 %		% 28.6 %		26.4 %
Business Advisory:								
Revenues	\$	69,966	\$	66,048	\$	213,741	\$	201,423
Operating income	\$	9,892	\$	10,780	\$	37,284	\$	37,306
Segment operating income as a percentage of segment revenues		14.1 %	б	16.3 %	ó	17.4 %	6	18.5 %
Education:								
Revenues	\$	61,196	\$	51,850	\$	169,681	\$	176,017
Operating income	\$	14,788	\$	12,548	\$	37,211	\$	41,792
Segment operating income as a percentage of segment revenues		24.2 %		24.2 %	ó	21.9 %		23.7 %
Total Company:								
Revenues	\$	224,007	\$	205,304	\$	657,346	\$	645,780
Reimbursable expenses		3,690		2,860		8,876		25,133
Total revenues and reimbursable expenses	\$	227,697	\$	208,164	\$	666,222	\$	670,913
Statements of Operations reconciliation:			_				_	
Segment operating income	\$	54,935	\$	48,938	\$	152,858	\$	149,929
Items not allocated at the segment level:								
Other operating expenses		31,374		29,042		94,536		87,826
Litigation and other losses (gains)		56		_		98		(150)
Depreciation and amortization		5,199		6,197		15,549		18,635
Goodwill impairment charges ⁽¹⁾		_		_		_		59,816
Operating income (loss)		18,306		13,699		42,675		(16,198)
Other expense, net		(2,611)		(224)		(3,788)		(6,829)
Income (loss) from continuing operations before taxes		15,695		13,475		38,887		(23,027)
Income tax expense (benefit)		1,968		2,388		6,958		(5,413)
Net income (loss) from continuing operations	\$	13,727	\$	11,087	\$	31,929	\$	(17,614)
Earnings (loss) per share from continuing operations:		<u> </u>		<u> </u>		·	_	
Basic	\$	0.65	\$	0.50	\$	1.48	\$	(0.81)
Diluted	\$	0.64	\$	0.50	\$	1.46	\$	(0.81)
	Ŧ		÷				·	()/



	Three Mo Septer				Nine Months Ended September 30,				
Other Operating Data:	 2021	2020 2021				2020			
Number of billable consultants (at period end) ⁽²⁾ :									
Healthcare	849		838		849		838		
Business Advisory	1,179		1,001		1,179		1,001		
Education	816		790		816		790		
Total	 2,844		2,629		2,844		2,629		
Average number of billable consultants (for the period) ⁽²⁾ :									
Healthcare	802		844		807		873		
Business Advisory	1,136		976		1,103		940		
Education	784		772		750		779		
Total	 2,722		2,592		2,660		2,592		
Billable consultant utilization rate ⁽³⁾ :									
Healthcare	74.9 %)	71.4 %	, D	72.7 %	ó	70.2 %		
Business Advisory	69.0 %)	72.6 %	, D	69.3 %	б	72.6 %		
Education	74.5 %)	66.5 %	, D	73.3 %	б	71.7 %		
Total	72.2 %)	70.4 %	Ď	71.5 %	ó	71.5 %		
Billable consultant average billing rate per hour ⁽⁴⁾ :									
Healthcare	\$ 229	\$	232	\$	232	\$	218		
Business Advisory ⁽⁵⁾	\$ 184	\$	186	\$	191	\$	197		
Education	\$ 193	\$	184	\$	186	\$	189		
Total ⁽⁵⁾	\$ 200	\$	200	\$	201	\$	201		
Revenue per billable consultant (in thousands):									
Healthcare	\$ 74	\$	71	\$	221	\$	203		
Business Advisory	\$ 57	\$	64	\$	182	\$	204		
Education	\$ 65	\$	57	\$	191	\$	194		
Total	\$ 64	\$	64	\$	196	\$	200		
Average number of full-time equivalents (for the period) ⁽⁶⁾ :									
Healthcare	149		191		154		188		
Business Advisory	59		35		50		27		
Education	 49		46		41		56		
Total	257		272		245		271		
Revenue per full-time equivalent (in thousands):									
Healthcare	\$ 133	\$	110	\$	392	\$	371		
Business Advisory	\$ 93	\$	106	\$	270	\$	370		
Education	\$ 203	\$	165	\$	643	\$	453		
Total	\$ 137	\$	119	\$	410	\$	388		
Healthcare Managed Services employees ⁽⁷⁾ :									
Total revenues (in thousands)	\$ 13,612	\$	6,423	\$	35,409	\$	21,493		
Average number of Healthcare Managed Services employees (for the period)	485		88		342		91		

(1) The non-cash goodwill impairment charges are not allocated at the segment level because the underlying goodwill asset is reflective of our corporate investment in the segments. We do not include the impact of goodwill impairment charges in our evaluation of segment performance.

(2) Consists of our consulting professionals who provide consulting services and generate revenues based on the number of hours worked.

(3) Utilization rate for our billable consultants is calculated by dividing the number of hours our billable consultants worked on client assignments during a period by the total available working hours for these consultants during the same period, assuming a forty-hour work week, less paid holidays and vacation days.

(4) Average billing rate per hour for our billable consultants is calculated by dividing revenues for a period by the number of hours worked on client assignments during the same period.

(5) The Business Advisory segment includes operations of Huron Eurasia India. Absent the impact of Huron Eurasia India, the average billing rate per hour for the Business Advisory segment would have been \$200 and \$201 for the three months ended September 30, 2021 and 2020, respectively; and \$207 and \$217 for the nine months ended September 30, 2021 and 2020, respectively.

Absent the impact of Huron Eurasia India, Huron's consolidated average billing rate per hour would have been \$207 and \$206 for the three months ended September 30, 2021 and 2020, respectively; and \$208 for both the nine months ended September 30, 2021 and 2020.

- (6) Consists of coaches and their support staff within our Culture and Organizational Excellence solution, consultants who work variable schedules as needed by our clients, and full-time employees who provide software support and maintenance services to our clients.
- (7) Consists of employees who manage and provide revenue cycle billing, collections, insurance verification and change integrity services to our healthcare clients.

Non-GAAP Measures

We also assess our results of operations using certain non-GAAP financial measures. These non-GAAP financial measures differ from GAAP because the non-GAAP financial measures we calculate to measure earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted EBITDA, adjusted EBITDA as a percentage of revenues, adjusted net income from continuing operations, and adjusted diluted earnings per share from continuing operations exclude a number of items required by GAAP, each discussed below. These non-GAAP financial measures should be considered in addition to, and not as a substitute for or superior to, any measure of performance, cash flows, or liquidity prepared in accordance with GAAP. Our non-GAAP financial measures may be defined differently from time to time and may be defined differently than similar terms used by other companies, and accordingly, care should be exercised in understanding how we define our non-GAAP financial measures.

Our management uses the non-GAAP financial measures to gain an understanding of our comparative operating performance, for example when comparing such results with previous periods or forecasts. These non-GAAP financial measures are used by management in their financial and operating decision making because management believes they reflect our ongoing business in a manner that allows for meaningful period-to-period comparisons. Management also uses these non-GAAP financial measures when publicly providing our business outlook, for internal management purposes, and as a basis for evaluating potential acquisitions and dispositions. We believe that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating Huron's current operating performance and future prospects in the same manner as management does and in comparing in a consistent manner Huron's current financial results with Huron's past financial results.

The reconciliations of these financial measures from GAAP to non-GAAP are as follows (in thousands, except per share amounts):

	Three Mo Septer					ths Ended 1ber 30,		
	 2021	2020		2021			2020	
Revenues	\$ 224,007	\$	205,304	\$	657,346	\$	645,780	
Net income (loss) from continuing operations	\$ 13,727	\$	11,087	\$	31,929	\$	(17,614)	
Add back:								
Income tax expense (benefit)	1,968		2,388		6,958		(5,413)	
Interest expense, net of interest income	2,217		2,259		5,965		7,516	
Depreciation and amortization	6,534		7,546		19,640		22,488	
Earnings before interest, taxes, depreciation and amortization (EBITDA)	 24,446		23,280		64,492		6,977	
Add back:								
Restructuring and other charges	1,677		59		3,166		2,626	
Litigation and other losses (gains)	56				98		(150)	
Goodwill impairment charges	_						59,816	
Loss on sale of business							102	
Transaction-related expenses	194		437		335		437	
Foreign currency transaction losses (gains), net	43		(194)		398		245	
Adjusted EBITDA	\$ 26,416	\$	23,582	\$	68,489	\$	70,053	
Adjusted EBITDA as a percentage of revenues	 11.8 %		11.5 %		10.4 %		10.8 %	

29

	Three Months Ended September 30,					Nine Mon Septen		
	2021			2020	2021			2020
Net income (loss) from continuing operations	\$	13,727	\$	11,087	\$	31,929	\$	(17,614)
Weighted average shares - diluted	-	21,531		22,175		21,904		21,868
Diluted earnings (loss) per share from continuing operations	\$	0.64	\$	0.50	\$	1.46	\$	(0.81)
Add back:								
Amortization of intangible assets		2,235		3,155		6,923		9,558
Restructuring and other charges		1,677		59		3,166		2,626
Litigation and other losses (gains)		56				98		(150)
Goodwill impairment charges		—				—		59,816
Loss on sale of business		—		—		—		102
Transaction-related expenses		194		437		335		437
Tax effect of adjustments		(1,103)		(1,692)		(2,788)		(17,041)
Total adjustments, net of tax		3,059		1,959		7,734		55,348
Adjusted net income from continuing operations	\$	16,786	\$	13,046	\$	39,663	\$	37,734
Adjusted weighted average shares - diluted		21,531		22,175		21,904		22,207
Adjusted diluted earnings per share from continuing operations	\$	0.78	\$	0.59	\$	1.81	\$	1.70

These non-GAAP financial measures include adjustments for the following items:

Amortization of intangible assets: We have excluded the effect of amortization of intangible assets from the calculation of adjusted net income from continuing operations presented above. Amortization of intangible assets is inconsistent in its amount and frequency and is significantly affected by the timing and size of our acquisitions.

Restructuring and other charges: We have incurred charges due to the restructuring of various parts of our business. These restructuring charges have primarily consisted of costs associated with office space consolidations, including lease impairment charges and accelerated depreciation on lease-related property and equipment, and severance charges. Additionally, we have excluded the effect of a \$0.8 million one-time charge incurred during the first quarter of 2020, related to redundant administrative costs in our corporate operations which is recorded within selling, general and administrative expenses on our consolidated statement of operations. We have excluded the effect of the restructuring and other charges from our non-GAAP measures to permit comparability with periods that were not impacted by these items.

Litigation and other losses (gains): We have excluded the effect of a loss in the first and third quarter of 2021 from an increase in the estimated fair value of our liability for contingent consideration related to a business acquisition and a litigation settlement gain recognized in the first quarter of 2020 to permit comparability with periods that were not impacted by these items.

Goodwill impairment charges: We have excluded the effect of the goodwill impairment charges recognized in the first quarter of 2020 as these charges are infrequent events and their exclusion permits comparability with periods that were not impacted by such charges.

Loss on sale of business: We excluded the effect of the loss on sale of a software-based solution within our Business Advisory segment in the first quarter of 2020. Divestitures of businesses are infrequent and are not indicative of the ongoing performance of our business.

Transaction-related expenses: To permit comparability with prior periods, we excluded the impact of third-party legal and accounting fees incurred in the first nine months of 2021 and 2020 related to business acquisitions.

Foreign currency transaction losses (gains), net: We have excluded the effect of foreign currency transaction losses and gains from the calculation of adjusted EBITDA because the amount of each loss or gain is significantly affected by changes in foreign exchange rates.

Tax effect of adjustments: The non-GAAP income tax adjustment reflects the incremental tax impact applicable to the non-GAAP adjustments.

Income tax expense, Interest expense, net of interest income, Depreciation and amortization: We have excluded the effects of income tax expense, interest expense, net of interest income, and depreciation and amortization in the calculation of EBITDA, as these are customary exclusions as defined by the calculation of EBITDA to arrive at meaningful earnings from core operations excluding the effect of such items. Included within the depreciation and amortization adjustment is the amortization of capitalized implementation costs of our ERP and other related software, which is included within selling, general and administrative expenses on our consolidated statement of operations.

Adjusted weighted average shares - diluted: As we reported a net loss for the first nine months of 2020, GAAP diluted weighted average shares outstanding equals the basic weighted average shares outstanding for that period. The non-GAAP adjustments described above resulted in adjusted net income from continuing operations for the first nine months of 2020. Therefore, we included the dilutive common stock equivalents in the calculation of adjusted diluted weighted average shares outstanding for that period.

Three Months Ended September 30, 2021 Compared to Three Months Ended September 30, 2020

Revenues

Revenues increased \$18.7 million, or 9.1%, to \$224.0 million for the third quarter of 2021 from \$205.3 million for the third quarter of 2020. The increase in revenues reflects strengthened demand for services in all of our segments, as well as the favorable comparison against results for the third quarter of 2020 in our Healthcare and Education segments which were more significantly impacted by the COVID-19 pandemic as some clients reprioritized and delayed certain projects as a result of the uncertainties surrounding the pandemic.

Of the \$18.7 million increase in revenues, \$8.6 million was attributable to an increase in revenues generated by our billable consultants, \$7.2 million was attributable to an increase in revenues generated by our Healthcare Managed Services employees, and \$2.9 million was attributable to revenues generated by our full-time equivalents.

The increase in billable consultant revenues reflected strengthened demand for services in our Education and Business Advisory segments, partially offset by a decrease in demand for certain services in our Healthcare segment, as discussed below in Segment Results. The overall increase in billable consultant revenues was primarily attributable to overall increases in the average number of billable consultants and the consultant utilization rate for the third quarter of 2021 compared to the same prior year period.

The increase in Healthcare Managed Services revenues was primarily attributable to an increase in demand for these services, which led to an increase in the average number of managed services employees in the third quarter of 2021 compared to the same prior year period. At the beginning of the second quarter of 2021, we hired approximately 300 employees to expand our capacity to manage and provide revenue cycle billing, collections, insurance verification and change integrity services to our healthcare clients. These employees are serving new and existing clients in our Healthcare Managed Services solution, including serving under a short-term contract with an existing client which we entered into in connection with this group hire.

The increase in full-time equivalent revenues was primarily attributable to an increase in full-time equivalent revenues in our Education and Business Advisory segments, as discussed below in Segment Results. The overall increase in full-time equivalent revenues reflected an overall increase in revenue per full-time equivalent, partially offset by an overall decrease in the average number of full-time equivalents in the third quarter of 2021 compared to the same prior year period.

In most of 2020 and the first quarter of 2021, the COVID-19 pandemic negatively impacted sales and elongated the sales cycle for new opportunities for certain services, particularly within our Healthcare and Education segments as some clients reprioritized or delayed certain projects. During the second and third quarters of 2021, we saw an increase in our sales pipeline and the pace of signings in our Healthcare and Education businesses. As the overall demand for our services continued to strengthen in the second and third quarters of 2021, we expect continued revenue growth in the fourth quarter of 2021 compared to the fourth quarter of 2020.

Total Direct Costs

Direct costs, excluding amortization of intangible assets and software development costs, increased \$8.4 million, or 5.8%, to \$153.9 million for the three months ended September 30, 2021, from \$145.5 million for the three months ended September 30, 2020. The \$8.4 million increase primarily related to a \$9.8 million increase in salaries and related expenses for our revenue-generating professionals, a \$1.0 million increase in signing, retention and other bonus expense for our revenue-generating professionals, a \$0.9 million increase in share-based compensation expense for our revenue-generating professionals, a \$0.7 million increase in contractor expense and a \$0.5 million increase in product and event costs. These increases in direct costs were partially offset by a \$4.5 million decrease in performance bonus expense for our revenue-generating professionals which primarily reflects a decrease in the performance bonus adjustment recorded in the third quarter of 2021 compared to the third quarter of 2020 to adjust our year-to-date performance bonus accrual to reflect the revised full year forecasts. As a percentage of revenues, direct costs decreased to 68.7% during the third quarter of 2021 compared to 70.9% during the third quarter of 2020, primarily due to the decrease in performance bonus expense for our revenue-generating professionals, partially offset by the increases in signing, retention and other bonus expense and share-based compensation expense for our revenue-generating professionals, as percentages of revenues.

Total direct costs for the three months ended September 30, 2021 included \$0.9 million of amortization expense for internal software development costs and intangible assets, compared to \$1.4 million of amortization expense for the same prior year period. Intangible asset amortization included within direct costs for the three months ended September 30, 2021 and 2020 primarily related to technology and software, certain customer relationships and customer contracts acquired in connection with our business acquisitions. See Note 4 "Goodwill and Intangible Assets" within the notes to our consolidated financial statements for additional information on our intangible assets.

Operating Expenses and Other Losses (Gains), Net

Selling, general and administrative expenses increased by \$5.0 million, or 12.9%, to \$43.5 million in the third quarter of 2021 from \$38.6 million in the third quarter of 2020. The overall \$5.0 million increase primarily related to a \$1.4 million increase in share-based compensation expense for our support personnel, a \$1.2 million increase in promotion and marketing expense, a \$1.1 million increase in salaries and related expenses for our support personnel, a \$0.8 million increase in software and data hosting expense, a \$0.6 million increase in signing, retention and other bonus

expense for our support personnel, a \$0.6 million increase in research expense, a \$0.6 million increase in legal expenses, a \$0.5 million increase in practice administration and meetings expense, and a \$0.5 million increase in third-party consulting expense. The increase in share-based compensation expense primarily related to a decrease in the expected funding of performance-based share awards for our executive officers recorded in the third quarter of 2020. These increases were partially offset by a \$2.2 million decrease in deferred compensation expense for our support personnel. During the third quarter of 2021, the market value of our deferred compensation liability, and a \$1.2 million decrease in expense is offset by a \$2.2 million decrease in expense is offset by a \$2.2 million decrease in expense is offset by a \$2.2 million decrease in the gain recognized for the change in the market value of 2021, the market value of our deferred compensation liability decrease in expense is offset by a \$2.2 million decrease in the gain recognized for the change in the market value of investments that are used to fund our deferred compensation liability and recognized in other income (expense), net. As a percentage of revenues, selling, general and administrative expenses increased to 19.4% during the third quarter of 2021 compared to 18.8% during the third quarter of 2020. This increase was primarily attributable to the increases in selling, general and administrative expenses described above, as percentages of revenues, partially offset by the decreases in deferred compensation expense and performance bonus expense for our support personnel.

Restructuring charges for the third quarter of 2021 were \$1.7 million, compared to \$0.1 million for the third quarter of 2020. The \$1.7 million of restructuring charges recognized in the third quarter of 2021 consisted of \$0.7 million of third-party transaction expenses related to the evaluation of the divestiture of our Life Sciences business within our Business Advisory segment, \$0.5 million of rent and related expenses, net of sublease income, for previously vacated office spaces, and \$0.5 million of employee-related expenses. The \$0.1 million of restructuring charges recognized in the third quarter of 2020 primarily related to rent and related expenses, net of sublease income, for vacated office spaces. See Note 8 "Restructuring Charges" within the notes to our consolidated financial statements for additional information on our restructuring charges.

Depreciation and amortization expense decreased \$0.8 million, or 12.4%, to \$5.4 million for the three months ended September 30, 2021 compared to \$6.2 million for the three months ended September 30, 2020. The \$0.8 million decrease in depreciation and amortization expense was primarily attributable to decreasing amortization expense for customer relationships acquired in business acquisitions due to the accelerated basis of amortization in prior periods, including the customer relationships acquired in our Studer Group acquisition; and customer relationships acquired in other business acquisitions that were fully amortized in prior periods; as well as a decrease in depreciation expense for leasehold improvements and furniture and fixtures related to vacated office spaces. Intangible asset amortization expense included within operating expenses primarily related to certain customer relationships, trade names, and non-competition agreements acquired in connection with our business acquisitions. See Note 4 "Goodwill and Intangible Assets" within the notes to our consolidated financial statements for additional information on our intangible assets.

Operating Income

Operating income increased \$4.6 million to \$18.3 million in the third quarter of 2021 from \$13.7 million in the third quarter of 2020. Operating margin, which is defined as operating income expressed as a percentage of revenues, was 8.2% for the three months ended September 30, 2021 compared to 6.7% for the three months ended September 30, 2020. The increase in operating margin was primarily attributable to the increase in revenues and the decreases in performance bonus expense for our revenue-generating professionals, deferred compensation expense, performance bonus expense for our support personnel, and depreciation and amortization expense, partially offset by the increases in share-based compensation expense for our support personnel and restructuring charges, as percentages of revenues.

Total Other Income (Expense), Net

Interest expense, net of interest income decreased less than \$0.1 million to \$2.2 million in the third quarter of 2021 from \$2.3 million in the third quarter of 2020. See Note 7 "Financing Arrangements" within the notes to our consolidated financial statements for additional information about our senior secured credit facility.

Other income (expense), net decreased \$2.4 million to other expense, net of \$0.4 million in the third quarter of 2021 from other income, net of \$2.0 million in the third quarter of 2020. The decrease in other income, net was primarily attributable to the \$2.2 million decrease in the gain recognized for the market value of our investments that are used to fund our deferred compensation liability. During the third quarter of 2021, we recognized a \$0.4 million loss for the market value of our deferred compensation investments compared to a \$1.8 million gain recognized in the third quarter of 2020.

Income Tax Expense

For the three months ended September 30, 2021, our effective tax rate was 12.5% as we recognized income tax expense from continuing operations of \$2.0 million on income from continuing operations of \$15.7 million. The effective tax rate of 12.5% was more favorable than the statutory rate, inclusive of state income taxes, of 26.6%, primarily due to a discrete tax benefit for U.S. federal return to provision adjustments related to the 2020 corporate income tax return.

For the three months ended September 30, 2020, our effective tax rate was 17.7% as we recognized income tax expense from continuing operations of \$2.4 million on income from continuing operations of \$13.5 million. The effective tax rate of 17.7% was more favorable than the statutory rate, inclusive of state income taxes, of 26.0%, primarily due to the year-to-date pre-tax losses and the impact during the quarter of certain nondeductible expense items, including the nondeductible portion of the goodwill impairment charges, based on the attribution of those expenses to the quarter in

accordance with the allocation of income tax expense on a year-to-date basis. The effective tax rate also reflected the positive impact of certain federal tax credits. See Note 4 "Goodwill and Intangible Assets" within the notes to our consolidated financial statements for additional information on the goodwill impairment charges recognized in the first quarter of 2020.

See Note 12 "Income Taxes" within the notes to our consolidated financial statements for additional information on our income tax expense.

Net Income from Continuing Operations and Earnings per Share

Net income from continuing operations increased \$2.6 million to \$13.7 million for the three months ended September 30, 2021 from \$11.1 million for the same period last year. As a result of the decrease in net income from continuing operations, diluted earnings per share from continuing operations for the third quarter of 2021 was \$0.64 compared to \$0.50 for the third quarter of 2020.

EBITDA and Adjusted EBITDA

EBITDA increased \$1.2 million to \$24.4 million for the three months ended September 30, 2021 from \$23.3 million for the three months ended September 30, 2020. Adjusted EBITDA increased \$2.8 million to \$26.4 million in the third quarter of 2021 from \$23.6 million in the third quarter of 2020. The increase in EBITDA was primarily attributable to an overall increase in segment operating income, partially offset by an increase in corporate expenses. The increase in adjusted EBITDA was primarily attributable to an increase in segment operating income, partially offset by an increase in corporate expenses, excluding the change in the market value of our deferred compensation liability for the third quarter of 2021 compared to the third quarter of 2020 and restructuring charges not allocated at the segment level. See Segment Results below for additional information on segment operating income.

Adjusted Net Income from Continuing Operations and Adjusted Earnings per Share

Adjusted net income from continuing operations increased \$3.7 million to \$16.8 million in the third quarter of 2021 compared to \$13.0 million in the third quarter of 2020. As a result of the increase in adjusted net income from continuing operations, adjusted diluted earnings per share from continuing operations was \$0.78 for the third quarter of 2021, compared to \$0.59 for the third quarter of 2020.

Segment Results

Healthcare

Revenues

Healthcare segment revenues increased \$5.4 million, or 6.2%, to \$92.8 million for the third quarter of 2021 from \$87.4 million for the third quarter of 2020 due to strengthened demand for services in this segment in the third quarter of 2021, as well as the favorable comparison against results for the third quarter of 2020 which was significantly impacted by the COVID-19 pandemic as some clients reprioritized and delayed certain projects as a result of the uncertainties surrounding the pandemic.

During the three months ended September 30, 2021, revenues from fixed-fee engagements; time-and-expense engagements; performancebased arrangements; and software support, maintenance and subscription arrangements represented 61.2%, 19.2%, 13.7%, and 5.9% of this segment's revenues, respectively, compared to 58.9%, 16.7%, 17.9%, and 6.5% of this segment's revenues, respectively, for the same prior year period. Performance-based fee revenue was \$12.7 million for the third quarter of 2021 compared to \$15.6 million for the third quarter of 2020. The level of performance-based fees earned may vary based on our clients' risk sharing preferences and the mix of services we provide.

Of the overall \$5.4 million increase in revenues, \$7.2 million was attributable to an increase in revenues from our Healthcare Managed Services employees, partially offset by a \$1.2 million decrease in revenues from our full-time equivalents and a \$0.6 million decrease in revenues from our billable consultants.

The increase in Healthcare Managed Services revenues was primarily attributable to an increase in demand for these services, which led to an increase in the average number of managed services employees in the third quarter of 2021 compared to the same prior year period. At the beginning of the second quarter of 2021, we hired approximately 300 employees to expand our capacity to manage and provide revenue cycle billing, collections, insurance verification and change integrity services to our healthcare clients. These employees are serving new and existing clients in our Healthcare Managed Services solution, including serving under a short-term contract with an existing client which we entered into in connection with this group hire.

The decrease in revenues from our full-time equivalents was primarily driven by a decrease in demand for certain services and a decreased use of contractors and project consultants; and reflected a decrease in the average number of full-time equivalents, partially offset by an increase in revenue per full-time equivalent in the third quarter of 2021 compared to the same prior year period.

The decrease in revenues attributable to our billable consultants reflected decreases in the average number of billable consultants and the average billing rate, partially offset by an increase in the consultant utilization rate in the third quarter of 2021 compared to the same prior year period.

Operating Income

Healthcare segment operating income increased \$4.6 million, or 18.1%, to \$30.3 million for the three months ended September 30, 2021 from \$25.6 million for the three months ended September 30, 2020. The Healthcare segment operating margin, defined as segment operating income expressed as a percentage of segment revenues, increased to 32.6% for the third quarter of 2021 from 29.3% in the same period last year. The increase in this segment's operating margin was primarily attributable to a decrease in performance bonus expense for our revenue-generating professionals as well as a decrease in salaries and related expenses for our support personnel. These increases to the operating margin were partially offset by increases in signing, retention and other bonus expense for our revenue-generating professionals and product and event costs, as percentages of revenues.

Business Advisory

Revenues

Business Advisory segment revenues increased \$3.9 million, or 5.9%, to \$70.0 million for the third quarter of 2021 from \$66.0 million for the third quarter of 2020, primarily related to strengthened demand for our strategy and innovation solutions and our cloud-based technology and analytics solutions. Revenues for the third quarter of 2021 included \$4.5 million from our acquisitions of ForceIQ and Unico Solutions, which were completed in November 2020 and February 2021, respectively.

During the three months ended September 30, 2021, revenues from fixed-fee engagements; time-and-expense engagements; performancebased arrangements; and software support, maintenance and subscription arrangements represented 44.0%, 50.4%, 2.3%, and 3.3% of this segment's revenues, respectively, compared to 31.3%, 61.3%, 5.6%, and 1.8% of this segment's revenues, respectively, for the same prior year period. Performance-based fee revenue was \$1.6 million for the third quarter of 2021 compared to \$3.7 million for the third quarter of 2020. The level of performance-based fees earned may vary based on our clients' preferences, the mix of services we provide, and the timing of transactions or milestones.

Of the overall \$3.9 million increase in revenues, \$2.1 million was attributable to an increase in revenues from our billable consultants and \$1.8 million was attributable to an increase in revenues from our full-time equivalents. The increase in revenues from our billable consultants reflected an increase in the average number of billable consultants, partially offset by decreases in the consultant utilization rate and the average billing rate in the third quarter of 2021 compared to the same prior year period. The increase in revenues generated by our full-time equivalents was primarily driven by an increased use of contractors and project consultants; and reflected an increase in the average number of full-time equivalents, partially offset by a decrease in revenue per full-time equivalent in the third quarter of 2021 compared to the same prior year period.

On November 1, 2021, we completed the divestiture of the Life Sciences business to Oliver Wyman. The Life Sciences business, a reporting unit within the Business Advisory segment, provides commercial and research and development strategy, pricing and market access strategy solutions to customers in the life sciences industries. For the three months ended September 30, 2021, Life Sciences revenues were \$5.1 million. The Life Sciences business is not significant to our consolidated financial statements and does not qualify as a discontinued operation for reporting under GAAP.

Operating Income

Business Advisory segment operating income decreased by \$0.9 million, or 8.2%, to \$9.9 million for the three months ended September 30, 2021 from \$10.8 million for the three months ended September 30, 2020. The Business Advisory segment operating margin decreased to 14.1% for the third quarter of 2021 from 16.3% in the same period last year. The decrease in this segment's operating margin was primarily attributable to increases in salaries and related expenses for our revenue-generating professionals and contractor expense, as percentages of revenues, as well as increases in restructuring charges, promotion and marketing expense and practice administration and meetings expense, as percentages of revenues. These decreases to the segment's operating margin were partially offset by a decrease in performance bonus expense for our revenue-generating professionals.

Education

Revenues

Education segment revenues increased \$9.3 million, or 18.0%, to \$61.2 million for the third quarter of 2021 from \$51.9 million for the third quarter of 2020 due to strengthened demand for services in this segment in the third quarter of 2021, as well as the favorable comparison against results for the third quarter of 2020 which was significantly impacted by the COVID-19 pandemic as some clients reprioritized and delayed certain projects as a result of the uncertainties surrounding the pandemic.

During the three months ended September 30, 2021, revenues from fixed-fee engagements; time-and-expense engagements; and software support, maintenance and subscription arrangements represented 24.5%, 63.4%, and 12.1% of this segment's revenues, respectively, compared to 21.1%, 67.9%, and 11.0% of this segment's revenues, respectively, for the same prior year period.

Of the overall \$9.3 million increase in revenues, \$7.0 million was attributable to an increase in revenues from our billable consultants and \$2.3 million was attributable to an increase in revenues from our full-time equivalents. The increase in revenues attributable to our billable consultants reflected increases in the consultant utilization rate, the average billing rate, and the average number of billable consultants in the third quarter of 2021 compared to the same prior year period. The increase in revenues from our full-time equivalents was primarily driven by an increase in software subscriptions and data hosting revenues, and reflected increases in revenue per full-time equivalent and the average number of full-time equivalents in the third quarter of 2021 compared to the same prior year period.

Operating Income

Education segment operating income increased \$2.2 million, or 17.9% to \$14.8 million for the three months ended September 30, 2021 from \$12.5 million for the three months ended September 30, 2020. The Education segment operating margin was 24.2% for both the third quarter of 2021 and 2020. This segment's revenue growth outpaced the increase in salaries and related expenses for our revenue-generating professionals. This increase to the segment's operating margin was largely offset by increases in performance bonus expense and share-based compensation expense for our revenue-generating professionals, as percentages of revenues.

Nine Months Ended September 30, 2021 Compared to Nine Months Ended September 30, 2020

Revenues

Revenues increased \$11.6 million, or 1.8%, to \$657.3 million for the first nine months of 2021 from \$645.8 million for the first nine months of 2020. The increase in revenues reflects strengthened demand for services in our Business Advisory and Healthcare segments, partially offset by a decrease in demand for services in our Education segment, as discussed below in Segment Results.

Of the overall \$11.6 million increase in revenues, \$13.9 million was attributable to an increase in revenues from our Healthcare Managed Services employees and \$2.0 million was attributable to an increase in revenues from our billable consultants, partially offset by a \$4.3 million decrease in revenues from our full-time equivalents.

The increase in Healthcare Managed Services revenues was primarily attributable to an increase in demand for these services, which led to an increase in the average number of Healthcare Managed Services employees in the first nine months of 2021 compared to the same prior year period. At the beginning of the second quarter of 2021, we hired approximately 300 employees to expand our capacity to manage and provide revenue cycle billing, collections, insurance verification and change integrity services to our healthcare clients. These employees are serving new and existing clients in our Healthcare Managed Services solution, including serving under a short-term contract with an existing client which we entered into in connection with this group hire.

The increase in billable consultant revenues was attributable to an increase in demand for services in our Business Advisory segment, largely offset by a decrease in demand for services in our Education segment, as discussed below in Segment Results. The overall increase in billable consultant revenues reflected an overall increase in the average number of billable consultants during the first nine months of 2021 compared to the same prior year period.

The decrease in full-time equivalent revenues was primarily attributable to a decrease in full-time equivalent revenues in our Healthcare segment, partially offset by increases in full-time equivalent revenues in our Business Advisory and Education segments, as discussed below in Segment Results; and reflected an overall decrease in the average number of full-time equivalents, partially offset by an overall increase in revenue per full-time equivalent during the first nine months of 2021 compared to the first nine months of 2020.

In most of 2020 and the first quarter of 2021, the COVID-19 pandemic negatively impacted sales and elongated the sales cycle for new opportunities for certain services, particularly within our Healthcare and Education segments as some clients reprioritized or delayed certain projects. During the second and third quarters of 2021, we saw an increase in our sales pipeline and the pace of signings in our Healthcare and Education businesses. While overall demand for our services in the first quarter of 2021 was negatively impacted by the COVID-19 pandemic, the overall demand for our services strengthened in the second and third quarters of 2021 and we expect continued revenue growth in the fourth quarter of 2021 compared to the fourth quarter of 2020.

The COVID-19 pandemic has caused the need for many companies to accelerate their digital transformation to drive operational efficiencies, better engage with their customers, and make better data-driven decisions. This has resulted in strong demand for our digital, technology and analytic offerings, particularly within our Business Advisory segment. Indicative of our expectations for future growth in this segment, we continue to make investments in these offerings, both organically and through strategic acquisitions, such as our acquisitions of ForcelQ in November 2020 and Unico Solutions in February 2021, and through the addition of new offerings and capabilities within this segment where we see strategic opportunities.

Total Direct Costs

Direct costs, excluding amortization of intangible assets and software development costs, increased \$12.3 million, or 2.7%, to \$463.5 million for the nine months ended September 30, 2021, from \$451.2 million for the nine months ended September 30, 2020. The overall \$12.3 million increase primarily related to a \$16.1 million increase in salaries and related expenses for our revenue-generating professionals and a \$2.4 million increase in

signing, retention and other bonus expense for our revenue-generating professionals, partially offset by a \$4.2 million decrease in performance bonus expense for our revenue-generating professionals and a \$1.8 million decrease in contractor expense. As a percentage of revenues, our direct costs increased to 70.5% during the first nine months of 2021 compared to 69.9% during the first nine months of 2020 primarily due to the increase in salaries and related expenses for our revenue-generating professionals, as a percentage of revenues, partially offset by the decrease in performance bonus expense for our revenue-generating professionals.

Total direct costs for the nine months ended September 30, 2021 included \$2.7 million of amortization expense for internal software development costs and intangible assets, compared to \$4.0 million of amortization expense for the same prior year period. Intangible asset amortization included within direct costs for the nine months ended September 30, 2021 and 2020 related to technology and software, certain customer relationships and customer contracts acquired in connection with our business acquisitions. See Note 4 "Goodwill and Intangible Assets" within the notes to our consolidated financial statements for additional information about our intangible assets.

Operating Expenses and Other Losses (Gains), Net

Selling, general and administrative expenses increased \$1.6 million, or 1.3%, to \$128.5 million in the nine months ended September 30, 2021 from \$126.9 million in the nine months ended September 30, 2020. The \$1.6 million increase primarily related to a \$1.7 million increase in software and data hosting expense, a \$1.6 million increase in deferred compensation expense, a \$1.4 million increase in legal expense, and a \$1.1 million increase in signing, retention and other bonus expense for our support personnel. The \$1.6 million increase in deferred compensation expense was attributable to the change in the market value of our deferred compensation liability. During the first nine months of 2021, the market value of our deferred compensation liability increase in the gain recognized for the change in the market value of investments that are used to fund our deferred compensation liability and recognized in other income (expense), net. These increases to selling, general and administrative expenses were largely offset by a \$3.7 million decrease in practice administration and marketing expense. As a percentage of revenues, selling, general and administrative expenses decreased to 19.5% for the first nine months of 2021 compared to 19.6% during the first nine months of 2020, primarily attributable to the decrease in practice administration and meetings expenses described above.

Restructuring charges for the first nine months of 2021 totaled \$3.2 million, compared to \$1.8 million for the first nine months of 2020. The \$3.2 million restructuring charge incurred in the first nine months of 2021 consisted of \$1.8 million of rent and related expenses, net of sublease income, and accelerated depreciation on furniture and fixtures for vacated office spaces, \$0.9 million of third-party transaction expenses related to the evaluation of the divestiture of our Life Sciences business within our Business Advisory segment, and \$0.5 million of employee-related expenses. The \$1.8 million restructuring charge incurred in the first nine months of 2020 primarily related to a \$1.2 million accrual for the termination of a third-party advisor agreement; \$0.3 million related to workforce reductions to better align resources with market demand; \$0.2 million related to rent and related expenses, net of sublease income, for office spaces previously vacated, and \$0.1 million related to workforce reductions in our corporate operations. See Note 8 "Restructuring Charges" within the notes to our consolidated financial statements for additional information on our restructuring charges.

Litigation and other losses (gains), net totaled a net loss of \$0.1 million for the nine months ended September 30, 2021, which consisted of remeasurement losses to increase the fair value of our liability for contingent consideration related to a business combination. Litigation and other losses (gains), net totaled a net gain of \$0.2 million for the nine months ended September 30, 2020, which consisted of a litigation settlement gain for the resolution of a claim that was settled in the first guarter of 2020.

Depreciation and amortization expense decreased by \$2.2 million, or 11.9%, to \$16.3 million for the nine months ended September 30, 2021, from \$18.5 million for the nine months ended September 30, 2020. The \$2.2 million decrease was primarily attributable to decreasing amortization expense for customer relationships acquired in business acquisitions due to the accelerated basis of amortization in prior periods, including the customer relationships acquired in our Studer Group acquisition; and customer relationships acquired in other business acquisitions that were fully amortized in prior periods; as well as a decrease in depreciation expense for leasehold improvements and furniture and fixtures related to vacated office spaces. Intangible asset amortization expense included within operating expenses primarily related to certain customer relationships, trade names, and non-competition agreements acquired in connection with our business acquisitions. See Note 4 "Goodwill and Intangible Assets" within the notes to our consolidated financial statements for additional information on our intangible assets.

During the first quarter of 2020, we recorded \$59.8 million of non-cash pretax goodwill impairment charges related to our Strategy and Innovation and Life Sciences reporting units within our Business Advisory segment; primarily related to the expected decline in sales, increased uncertainty in the backlog and a decrease in the demand for the services these reporting units provide, as a result of the COVID-19 pandemic. These charges were non-cash in nature and did not affect our liquidity or debt covenants. See Note 4 "Goodwill and Intangible Assets" within the notes to our consolidated financial statements for additional information on the charges.

Operating Income (Loss)

Operating income increased \$58.9 million to income of \$42.7 million in the first nine months of 2021 from a loss of \$16.2 million in the first nine months of 2020. This increase is primarily attributable to the \$59.8 million of non-cash pretax goodwill impairment charges recognized in the first

quarter of 2020 related to our Business Advisory segment. Operating margin, which is defined as operating income (loss) expressed as a percentage of revenues, was 6.5% for the nine months ended September 30, 2021, compared to (2.5)% for the nine months ended September 30, 2020. The increase in operating margin was primarily attributable to the goodwill impairment charges recognized in the first quarter of 2020, as well as the increase in revenues and decreases in performance bonus expense for our revenue-generating professionals and practice administration and meetings expenses. These increases to the operating margin were partially offset by the increase in salaries and related expenses for our revenue-generating professionals, as a percentage of revenues.

Total Other Income (Expense), Net

Interest expense, net of interest income decreased \$1.6 million to \$6.0 million in the first nine months of 2021 from \$7.5 million in the first nine months of 2020, primarily attributable to lower levels of borrowing under our credit facility during the first nine months of 2021 compared to the same prior year period. See Note 7 "Financing Arrangements" within the notes to our consolidated financial statements for additional information about our senior secured credit facility.

Other income (expense), net increased by \$1.5 million to a net gain of \$2.2 million in the first nine months of 2021 from a net gain of \$0.7 million in the first nine months of 2020. The increase in total other income, net was primarily attributable to the \$2.6 million gain recognized during the first nine months of 2021 for the market value of our investments that are used to fund our deferred compensation liability, compared to the \$1.0 million gain recognized during the first nine months of 2020.

Income Tax Expense (Benefit)

For the nine months ended September 30, 2021, our effective tax rate was 17.9% as we recognized income tax expense from continuing operations of \$7.0 million on income from continuing operations of \$38.9 million. The effective tax rate of 17.9% was more favorable than the statutory rate, inclusive of state income taxes, of 26.6% primarily due to a discrete tax benefit recognized in the third quarter of 2021 related to U.S. federal return to provision adjustments related to the 2020 corporate income tax return. The effective tax rate also reflected the positive impact of certain federal tax credits and a discrete tax benefit recognized during the second quarter of 2021 related to electing the Global Intangible Low-Taxed Income ("GILTI") high-tax exclusion retroactively for the 2018 tax year. On July 20, 2020, the U.S. Treasury issued and enacted final regulations related to GILTI that allow certain U.S. taxpayers to elect to exclude foreign income that is subject to a high effective tax rate from their GILTI inclusions. The GILTI high-tax exclusion is an annual election and is retroactively available. These favorable items were partially offset by certain nondeductible business expenses.

For the nine months ended September 30, 2020, our effective tax rate was 23.5% as we recognized an income tax benefit from continuing operations of \$5.4 million on a loss from continuing operations of \$23.0 million. The effective tax rate of 23.5% was less favorable than the statutory rate, inclusive of state income taxes, of 26.0%, primarily due to certain nondeductible business expenses and the nondeductible portion of the goodwill impairment charges recorded during the first quarter of 2020. These unfavorable items were partially offset by a discrete tax benefit for share-based compensation awards that vested during the first quarter, the positive impact of certain federal tax credits, and a discrete tax benefit for the remeasurement portion of our income tax receivable as a result of the enactment of the CARES Act in the first quarter of 2020.

The CARES Act, which was signed into law on March 27, 2020, is an approximately \$2 trillion emergency economic stimulus package in response to the COVID-19 outbreak, which among other items, includes income tax provisions relating to net operating loss carryback periods and technical corrections to tax depreciation methods for qualified improvement property. In the first nine months of 2020, as a result of the CARES Act, we recognized a \$0.8 million tax benefit related to the remeasurement of a portion of our income tax receivable due to the ability to apply the federal net operating loss incurred in 2018 to prior year income for a refund at the higher tax rate in the carryback period. As a result of electing the retroactive GILTI high-tax exclusion in the second quarter of 2021, we recognized a \$1.0 million tax benefit of which \$0.4 million related to carrying back our increased 2018 federal net operating loss to prior year income for a refund at the higher, prior year tax rate. During the third quarter of 2021, we recognized an additional tax benefit of \$2.0 million primarily related to the U.S. federal return to provision adjustments for carrying back our increased 2020 federal net operating loss to prior year income for a refund at the higher, prior year tax rate.

See Note 12 "Income Taxes" within the notes to our consolidated financial statements for additional information on our income tax expense.

Net Income (Loss) from Continuing Operations and Earnings (Loss) Per Share

Net income from continuing operations increased by \$49.5 million to net income from continuing operations of \$31.9 million for the nine months ended September 30, 2021, from a net loss from continuing operations of \$17.6 million for the same prior year period. This increase is primarily attributable to the \$59.8 million of non-cash pretax goodwill impairment charges recognized in the first quarter of 2020 related to our Business Advisory segment. As a result of the increase in net income from continuing operations, diluted earnings per share from continuing operations for the first nine months of 2021 was \$1.46 compared to a loss per share from continuing operations of \$0.81 for the first nine months of 2020. The non-cash goodwill impairment charges had a \$2.11 unfavorable impact on diluted earnings per share from continuing operations for the first nine months of 2020.

EBITDA and Adjusted EBITDA

EBITDA increased \$57.5 million to \$64.5 million for the nine months ended September 30, 2021, from \$7.0 million for the nine months ended September 30, 2020. The increase in EBITDA was primarily attributable to the non-cash goodwill impairment charges of \$59.8 million recognized in the first quarter of 2020. Adjusted EBITDA decreased \$1.6 million to \$68.5 million in the first nine months of 2021 from \$70.1 million in the first nine months of 2020. The decrease in adjusted EBITDA was primarily attributable to an increase in corporate expenses, excluding the change in the market value of our deferred compensation liability for the first nine months of 2021 compared to the first nine months of 2020 and restructuring charges not allocated at the segment level, partially offset by the overall increase in segment operating income, excluding depreciation and amortization and restructuring charges allocated at the segment level. See Segment Results below for additional information on segment operating income.

Adjusted Net Income from Continuing Operations and Adjusted Earnings per Share

Adjusted net income from continuing operations increased \$1.9 million to \$39.7 million in the first nine months of 2021 compared to \$37.7 million in the first nine months of 2020. As a result of the increase in adjusted net income from continuing operations, adjusted diluted earnings per share from continuing operations for the first nine months of 2021 was \$1.81 compared to \$1.70 for the first nine months of 2020.

Segment Results

Healthcare

Revenues

Healthcare segment revenues increased \$5.6 million, or 2.1%, to \$273.9 million for the first nine months of 2021 from \$268.3 million for the first nine months of 2020. The overall increase was primarily due to strengthened demand for this segment's services in the second and third quarters of 2021 and the favorable comparison against the first nine months of 2020, which was more significantly impacted by the COVID-19 pandemic as some clients reprioritized and delayed certain projects as a result of the uncertainties surrounding the pandemic.

During the nine months ended September 30, 2021, revenues from fixed-fee engagements; time-and-expense engagements; performancebased arrangements; and software support, maintenance and subscription arrangements represented 58.5%, 17.2%, 18.4%, and 5.9% of this segment's revenues, respectively, compared to 58.9%, 16.2%, 18.3%, and 6.6% of this segment's revenues, respectively, for the same prior year period. Performance-based fee revenue was \$50.4 million during the first nine months of 2021, compared to \$49.0 million during the first nine months of 2020. The level of performance-based fees earned may vary based on our clients' risk sharing preferences and the mix of services we provide.

Of the overall \$5.6 million increase in revenues, \$13.9 million was attributable to an increase in revenues from our Healthcare Managed Services employees and \$0.9 million was attributable to an increase in revenues from our billable consultants, partially offset by a \$9.2 million decrease in revenues from our full-time equivalents.

The increase in revenues attributable to our Healthcare Managed Services employees was primarily attributable to an increase in demand for these services, which led to an increase in the average number of managed services employees in the first nine months of 2021 compared to the same prior year period. At the beginning of the second quarter of 2021, we hired approximately 300 employees to expand our capacity to manage and provide revenue cycle billing, collections, insurance verification and change integrity services to our healthcare clients. These employees are serving new and existing clients in our Healthcare Managed Services solution, including serving under a short-term contract with an existing client which we entered into in connection with this group hire.

The increase in revenues attributable to our billable consultants reflected increases in the average billing rate and the consultant utilization rate, largely offset by a decrease in the average number of billable consultants during the first nine months of 2021 compared to the same prior year period.

The decrease in full-time equivalent revenues was primarily driven by a decrease in demand for certain services and a decreased use of contractors and project consultants; and reflected a decrease in the average number of full-time equivalents, partially offset by an increase in revenue per full-time equivalent in the first nine months of 2021 compared to the same prior year period.

Operating Income

Healthcare segment operating income increased \$7.5 million, or 10.6%, to \$78.4 million for the nine months ended September 30, 2021, from \$70.8 million for the nine months ended September 30, 2020. The Healthcare segment operating margin increased to 28.6% for the first nine months of 2021 from 26.4% in the same period last year. The increase in this segment's operating margin was primarily attributable to decreases in practice administration and meetings expense, contractor expense, and salaries and related expenses for our support personnel. These increases to the segment operating margin were partially offset by an increase in signing, retention and other bonus expense for our revenue-generating professionals, as a percentage of revenues.

Business Advisory

Revenues

Business Advisory segment revenues increased \$12.3 million, or 6.1%, to \$213.7 million for the first nine months of 2021 from \$201.4 million for the first nine months of 2020, primarily related to strengthened demand for our cloud-based technology and analytics solutions and our strategy and innovation solutions. Revenues for the first nine months of 2021 included \$11.9 million from our acquisitions of ForceIQ and Unico Solutions, which were completed in November 2020 and February 2021, respectively.

During the first nine months of 2021, revenues from fixed-fee engagements; time-and-expense engagements; performance-based arrangements; and software support, maintenance and subscription arrangements represented 43.0%, 50.9%, 3.1%, and 3.0% of this segment's revenues, respectively, compared to 36.5%, 58.8%, 2.9%, and 1.8% of this segment's revenues, respectively, during the same prior year period. Performance-based fee revenue was \$6.5 million for the first nine months of 2021, compared to \$5.9 million for the first nine months of 2020. The level of performance-based fees earned may vary based on our clients' preferences and the mix of services we provide.

Of the overall \$12.3 million increase in revenues, \$8.8 million was attributable to revenues generated by our billable consultants and \$3.5 million was attributable to our full-time equivalents. The increase in revenues from our billable consultants was primarily driven by an increase in the average number of billable consultants, partially offset by decreases in the consultant utilization rate and the average billing rate in the first nine months of 2021 compared to the same prior year period. The increase in revenues from our full-time equivalents was driven by an increased use of contractors and project consultants; and reflected an increase in the average number of full-time equivalents, partially offset by a decrease in revenue per full-time equivalent in the first nine months of 2021 compared to the same prior year period.

On November 1, 2021, we completed the divestiture of the Life Sciences business to Oliver Wyman. The Life Sciences business, a reporting unit within the Business Advisory segment, provides commercial and research and development strategy, pricing and market access strategy solutions to customers in the life sciences industries. For the nine months ended September 30, 2021, Life Sciences revenues were \$14.8 million. The Life Sciences business is not significant to our consolidated financial statements and does not qualify as a discontinued operation for reporting under GAAP.

Operating Income

Business Advisory segment operating income was \$37.3 million for both the nine months ended September 30, 2021 and 2020. The Business Advisory segment operating margin decreased to 17.4% for the first nine months of 2021 from 18.5% in the same period last year. The decrease in this segment's operating margin was primarily attributable to increases in salaries and related expenses for our revenue-generating professionals, contractor expense, and salaries and related expenses for our support personnel, as percentages of revenues; partially offset by decreases in performance bonus expense for our revenue-generating professionals and restructuring charges.

The first quarter 2020 non-cash goodwill impairment charges related to the Strategy and Innovation and Life Sciences reporting units within the Business Advisory segment, which are discussed above within consolidated results, are not allocated at the segment level because the underlying goodwill asset is reflective of our corporate investment in the segment. We do not include the impact of goodwill impairment charges in our evaluation of segment performance. See Note 4 "Goodwill and Intangible Assets" within the notes to our consolidated financial statements for additional information on the goodwill impairment charges recorded in the first quarter of 2020 and our goodwill balances.

Education

Revenues

Education segment revenues decreased \$6.3 million, or 3.6%, to \$169.7 million for the first nine months of 2021 from \$176.0 million for the first nine months of 2020. The decrease in revenues was primarily related to the negative impact of the COVID-19 pandemic on demand for this segment's services beginning in the third quarter of 2020 and continuing through the second quarter of 2021 as some clients reprioritized and delayed certain projects as a result of the uncertainties surrounding the pandemic. The decrease in revenues is also reflective of the difficult prior year comparison driven by the strong growth of this segment's revenues in the first half of 2020 prior to the impact of the pandemic on this segment.

For the nine months ended September 30, 2021, revenues from fixed-fee engagements; time-and-expense engagements; and software support, maintenance and subscription arrangements represented 28.4%, 59.3%, and 12.3% of this segment's revenues, respectively. During the same prior year period, revenues from fixed-fee engagements; time-and-expense engagements; performance-based arrangements; and software support, maintenance and subscription arrangements represented 20.2%, 70.1%, 0.4% and 9.3% of this segment's revenues, respectively.

Of the overall \$6.3 million decrease in revenues, \$7.8 million was attributable to a decrease in revenues generated by our billable consultants, partially offset by a \$1.5 million increase in revenues generated by our full-time equivalents. The decrease in revenues from our full-time billable consultants reflected decreases in the average number of billable consultants and the average billing rate, partially offset by an increase in the consultant utilization rate in the first nine months of 2021 compared to the same prior year period. The increase in revenues from our full-time equivalents was primarily driven by an increase in software subscriptions, software support and maintenance, and data hosting revenues, partially

offset by a decreased use of contractors and project consultants. The overall increase in full-time equivalent revenues reflected an increase in revenue per full-time equivalent, partially offset by a decrease in the average number of full-time equivalents in the first nine months of 2021 compared to the same prior year period.

Operating Income

Education segment operating income decreased \$4.6 million, or 11.0%, to \$37.2 million for the nine months ended September 30, 2021, from \$41.8 million for the nine months ended September 30, 2020. The Education segment operating margin decreased to 21.9% for the first nine months of 2021 from 23.7% in the same period last year. The decrease in this segment's operating margin was primarily attributable to an increase in performance bonus expense for our revenue-generating professionals and an increase in salaries and related expenses for our revenue-generating professionals as a percentage of revenues. These increases to the segment's operating margin were partially offset by a decrease in contractor expense, as a percentage of revenues.

LIQUIDITY AND CAPITAL RESOURCES

Cash and cash equivalents decreased \$56.0 million to \$11.2 million at September 30, 2021 from \$67.2 million at December 31, 2020. As of September 30, 2021, our primary sources of liquidity are cash on hand, cash flows from our U.S. operations, and borrowing capacity available under our credit facility.

	Nine Months Ended September 30,					
Cash Flows (in thousands):	2021			2020		
Net cash provided by (used in) operating activities	\$	(28,206)	\$	77,985		
Net cash used in investing activities		(18,726)		(28,388)		
Net cash provided by (used in) financing activities		(9,245)		13,517		
Effect of exchange rate changes on cash		189		27		
Net increase (decrease) in cash and cash equivalents	\$	(55,988)	\$	63,141		

Operating Activities

Net cash used in operating activities totaled \$28.2 million for the nine months ended September 30, 2021, compared to net cash provided by operating activities of \$78.0 million for the nine months ended September 30, 2020. Our operating assets and liabilities consist primarily of receivables from billed and unbilled services, accounts payable and accrued expenses, accrued payroll and related benefits, and deferred revenues. The volume of services rendered and the related billings and timing of collections on those billings, as well as payments of our accounts payable and salaries, bonuses, and related benefits to employees affect these account balances.

The decrease in net operating cash flows for the first nine months of 2021 compared to the same prior year period was primarily attributable to a decrease in cash collections in the first nine months of 2021 compared to the same prior year period and the \$12.2 million payment in the third quarter of 2021 of the employer's portion of social security taxes deferred under the CARES Act. These decreases to net operating cash flows were partially offset by a decrease in the amount paid for annual performance bonuses in the first quarter of 2021 compared to the first quarter of 2020.

Investing Activities

Net cash used in investing activities was \$18.7 million and \$28.4 million for the nine months ended September 30, 2021 and 2020, respectively.

The use of cash in the first nine months of 2021 primarily consisted of \$8.9 million for purchases of property and equipment, primarily related to purchases of leasehold improvements and furniture for certain office spaces and computers and related equipment; \$5.9 million for the purchase of a business; and \$3.6 million for payments related to internally developed software.

The use of cash in the first nine months of 2020 primarily consisted of \$13.0 million for the purchase of an additional convertible debt investment in

Shorelight Holdings, LLC; \$6.8 million for payments related to internally developed software; \$5.7 million for purchases of property and equipment, primarily related to purchases of leasehold improvements and furniture for certain office spaces and computers and related equipment; and \$2.0 million for contributions to our life insurance policies which fund our deferred compensation plan.

We estimate that cash utilized for purchases of property and equipment and software development in 2021 will total approximately \$13 million to \$17 million; primarily consisting of leasehold improvements for certain office locations, software development costs, and information technology equipment.

Financing Activities

Net cash used in financing activities was \$9.2 million for the nine months ended September 30, 2021. During the first nine months of 2021, we borrowed \$189.0 million under our credit facility, primarily to fund our operations, including our annual performance bonus payment in the first quarter of 2021, and made repayments on our borrowings of \$129.4 million. Additionally, during the first nine months of 2021, we repurchased and retired \$60.2 million of our common stock under our 2020 Share Repurchase Program, as defined below.

Net cash provided by financing activities was \$13.5 million for the nine months ended September 30, 2020. During the first nine months of 2020, we borrowed \$283.0 million under our credit facility, including \$125.0 million prior to March 31, 2020 to maintain excess cash and support liquidity during the period of uncertainty created by the COVID-19 pandemic, as well as to fund our annual performance bonus payment. During the first nine months of 2020, we made repayments on our borrowings of \$240.4 million, including \$200.0 million in the second and third quarters of 2020 due to our ability to maintain adequate cash flows from operations and improved clarity around access to capital resources. Additionally, we repurchased and retired \$20.9 million of our common stock under our 2015 Share Repurchase Program, as defined below, and settled \$1.2 million of share repurchases that were accrued as of December 31, 2019.

Share Repurchase Program

In November 2020, our board of directors authorized a share repurchase program (the "2020 Share Repurchase Program") permitting us to repurchase up to \$50 million of our common stock through December 31, 2021. The 2020 Share Repurchase Program was authorized subsequent to the expiration of our prior share repurchase program (the "2015 Share Repurchase Program") on October 31, 2020. The 2015 Share Repurchase Program permitted us to repurchase up to \$125 million of our common stock through October 31, 2020. During the third quarter of 2021, our board of directors authorized an extension of the 2020 Share Repurchase Program through December 31, 2022 and increased the authorized amount from \$50 million to \$100 million. The amount and timing of repurchases under both share repurchase programs were and will continue to be determined by management and depend on a variety of factors, including the trading price of our common stock, capacity under our credit facility, general market and business conditions, and applicable legal requirements.

In the three and nine months ended September 30, 2021, we repurchased and retired 518,045 and 1,169,126 shares for \$25.0 million and \$60.2 million, respectively, under the 2020 Share Repurchase Program. In the first quarter of 2020, we repurchased 313,998 shares for \$20.9 million under the 2015 Share Repurchase Program. Additionally, in the first quarter of 2020, we settled the repurchase of 18,000 shares for \$1.2 million that were accrued as of December 31, 2019. No shares were repurchased in the second or third quarters of 2020. As of September 30, 2021, \$34.7 million remained available for share repurchases under the 2020 Share Repurchase Program.

Financing Arrangements

At September 30, 2021, we had \$260.0 million outstanding under our senior secured credit facility and \$2.9 million outstanding under a promissory note, as discussed below.

Senior Secured Credit Facility

The Company has a \$600 million senior secured revolving credit facility, subject to the terms of a Second Amended and Restated Credit Agreement dated as of March 31, 2015, as amended to date (as amended and modified the "Amended Credit Agreement"), that becomes due and payable in full upon maturity on September 27, 2024. The Amended Credit Agreement provides the option to increase the revolving credit facility or establish term loan facilities in an aggregate amount of up to \$150 million, subject to customary conditions and the approval of any lender whose commitment would be increased, resulting in a maximum available principal amount under the Amended Credit Agreement of \$750 million. Borrowings under the Amended Credit Agreement may be used for working capital, capital expenditures, acquisitions of businesses, share repurchases, and general corporate purposes.

Fees and interest on borrowings vary based on our Consolidated Leverage Ratio (as defined in the Amended Credit Agreement). At our option, borrowings under the Amended Credit Agreement will bear interest at one, two, three or six-month LIBOR or an alternate base rate, in each case plus the applicable margin. The applicable margin will fluctuate between 1.125% per annum and 1.875% per annum, in the case of LIBOR borrowings, or between 0.125% per annum and 0.875% per annum, in the case of base rate loans, based upon our Consolidated Leverage Ratio at such time.

Amounts borrowed under the Amended Credit Agreement may be prepaid at any time without premium or penalty. We are required to prepay the amounts outstanding under the Amended Credit Agreement in certain circumstances. In addition, we have the right to permanently reduce or terminate the unused portion of the commitments provided under the Amended Credit Agreement at any time.

The Amended Credit Agreement contains usual and customary representations and warranties; affirmative and negative covenants, which include limitations on liens, investments, additional indebtedness, and restricted payments; and two quarterly financial covenants as follows: (i) a maximum Consolidated Leverage Ratio (defined as the ratio of debt to consolidated EBITDA) of 3.75 to 1.00; however the maximum permitted Consolidated Leverage Ratio will increase to 4.00 to 1.00 upon the occurrence of certain transactions, and (ii) a minimum Consolidated Interest Coverage Ratio (defined as the ratio of consolidated EBITDA to interest) of 3.50 to 1.00. Consolidated EBITDA for purposes of the financial covenants is calculated

on a continuing operations basis and includes adjustments to add back non-cash goodwill impairment charges, share-based compensation costs, certain non-cash restructuring charges, pro forma historical EBITDA for businesses acquired, and other specified items in accordance with the Amended Credit Agreement. For purposes of the Consolidated Leverage Ratio, total debt is on a gross basis and is not netted against our cash balances. At September 30, 2021 and December 31, 2020, we were in compliance with these financial covenants. Our Consolidated Leverage Ratio as of September 30, 2021 was 2.73 to 1.00, compared to 1.94 to 1.00 as of December 31, 2020. Our Consolidated Interest Coverage Ratio as of September 30, 2021 was 13.99 to 1.00, compared to 12.51 to 1.00 as of December 31, 2020.

The Amended Credit Agreement contains restricted payment provisions, including a potential limit on the amount of dividends we may pay. Pursuant to the terms of the Amended Credit Agreement, if our Consolidated Leverage Ratio is greater than 3.25, the amount of dividends and other Restricted Payments (as defined in the Amended Credit Agreement) we may pay is limited to an amount up to \$25 million.

Principal borrowings outstanding under the Amended Credit Agreement at September 30, 2021 and December 31, 2020 totaled \$260.0 million and \$200.0 million, respectively. These borrowings carried a weighted average interest rate of 2.7% at September 30, 2021 and 2.5% at December 31, 2020, including the impact of the interest rate swaps described in Note 9 "Derivative Instruments and Hedging Activity" within the notes to the consolidated financial statements. The borrowing capacity under the revolving credit facility is reduced by any outstanding borrowings under the revolving credit facility and outstanding letters of credit. At September 30, 2021, we had outstanding letters of credit totaling \$0.7 million, which are primarily used as security deposits for our office facilities. As of September 30, 2021, the unused borrowing capacity under the revolving credit facility was \$339.3 million.

Promissory Note due 2024

On June 30, 2017, in conjunction with our purchase of an aircraft related to the acquisition of Innosight, we assumed, from the sellers of the aircraft, a promissory note with an outstanding principal balance of \$5.1 million. The principal balance of the promissory note is subject to scheduled monthly principal payments until the maturity date of March 1, 2024, at which time a final payment of \$1.5 million, plus any accrued and unpaid interest, will be due. Under the terms of the promissory note, we will pay interest on the outstanding principal amount at a rate of one-month LIBOR plus 1.97% per annum. The obligations under the promissory note are secured pursuant to a Loan and Aircraft Security Agreement with Banc of America Leasing & Capital, LLC, which grants the lender a first priority security interest in the aircraft. At September 30, 2021, the outstanding principal amount of the promissory note was \$2.9 million, and the aircraft had a carrying amount of \$4.4 million.

For further information, see Note 7 "Financing Arrangements" within the notes to the consolidated financial statements.

Future Financing Needs

Throughout 2020 and into 2021, our primary financing need was to support our operations and maintain our liquidity during the COVID-19 pandemic. As such, we took proactive measures to increase available cash on hand, including, but not limited to, borrowing under our senior secured credit facility, reducing discretionary operating and capital expenses, and electing to defer the deposit of our employer portion of social security taxes as provided for under the CARES Act.

Given improved visibility to our project backlog and access to capital resources, our primary financing need has now returned to funding our long-term growth. Our growth strategy is to expand our service offerings, which may require investments in new hires, acquisitions of complementary businesses, possible expansion into other geographic areas, and related capital expenditures. We believe our internally generated liquidity, together with our available cash, and the borrowing capacity available under our revolving credit facility will be adequate to support our current financing needs and long-term growth strategy. Our ability to secure additional financing, if needed, in the future will depend on several factors, including our future profitability, the quality of our accounts receivable and unbilled services, our relative levels of debt and equity, and the overall condition of the credit markets.

CONTRACTUAL OBLIGATIONS

For a summary of our commitments to make future payments under contractual obligations, see Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations – Contractual Obligations" in our Annual Report on Form 10-K for the year ended December 31, 2020. As of September 30, 2021, borrowings outstanding under our senior secured credit facility totaled \$260.0 million compared to \$200.0 million at December 31, 2020. See the "Liquidity and Capital Resources" section above and Note 7 "Financing Arrangements" within the notes to our consolidated financial statements for additional information on our outstanding borrowings as of September 30, 2021. There have been no other material changes to our contractual obligations since December 31, 2020.

OFF-BALANCE SHEET ARRANGEMENTS

We are not a party to any material off-balance sheet arrangements.

CRITICAL ACCOUNTING POLICIES

Management's discussion and analysis of financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). We regularly review our financial reporting and disclosure practices and accounting policies to ensure that our financial reporting and disclosures provide accurate information relative to the current economic and business environment. The preparation of financial statements in conformity with GAAP requires management to make assessments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those policies that we believe present the most complex or subjective measurements and have the most potential to impact our financial position and operating results. While all decisions regarding accounting policies are important, we believe there are five accounting policies that could be considered critical: revenue recognition, allowances for doubtful accounts and unbilled services, business combinations, carrying values of goodwill and other intangible assets, and accounting for income taxes. For a detailed discussion of these critical accounting policies, see Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies" in our Annual Report on Form 10-K for the year ended December 31, 2020. There have been no material changes to our critical accounting policies during the first nine months of 2021.

NEW ACCOUNTING PRONOUNCEMENTS

See Note 3 "New Accounting Pronouncements" within the notes to the consolidated financial statements for information on new accounting pronouncements.

SUBSEQUENT EVENTS

On November 1, 2021, we completed the divestiture of our Life Sciences business to Oliver Wyman. The Life Sciences business, a reporting unit within the Business Advisory segment, provides commercial and research and development strategy, pricing and market access strategy solutions to customers in the life sciences industries. For the three and nine months ended September 30, 2021, Life Sciences revenues were \$5.1 million and \$14.8 million, respectively. The Life Sciences business is not significant to our consolidated financial statements and does not qualify as a discontinued operation for reporting under GAAP.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We are exposed to market risks primarily from changes in interest rates and changes in the market value of our investments.

Market Risk and Interest Rate Risk

We have exposure to changes in interest rates associated with borrowings under our bank credit facility, which has variable interest rates tied to LIBOR or an alternate base rate, at our option. At September 30, 2021, we had borrowings outstanding under the credit facility totaling \$260.0 million that carried a weighted average interest rate of 2.7%, including the impact of the interest rate swaps described below. A hypothetical 100 basis point change in the interest rate would have a \$0.6 million effect on our pretax income on an annualized basis, including the effect of the interest rate swaps. At December 31, 2020, we had borrowings outstanding under the credit facility totaling \$200.0 million that carried a weighted average interest rate of 2.5% including the impact of the interest rate swaps. As of December 31, 2020, these variable rate borrowings were fully hedged against changes in interest rates by the interest rate swaps, which have a notional amount of \$200.0 million. A hypothetical 100 basis point change in the interest rate would have had no impact on our pretax income, on an annualized basis, including the effect of the interest rate swaps.

On June 22, 2017, we entered into a forward interest rate swap agreement effective August 31, 2017 and ending August 31, 2022, with a notional amount of \$50.0 million. We entered into this derivative instrument to hedge against the interest rate risks of our variable-rate borrowings. Under the terms of the interest rate swap agreement, we receive from the counterparty interest on the notional amount based on one-month LIBOR and we pay to the counterparty a fixed rate of 1.900%.

On January 30, 2020, we entered into a forward interest rate swap agreement effective December 31, 2019 and ending December 31, 2024, with a notional amount of \$50.0 million. We entered into this derivative instrument to further hedge against the interest rate risks of our variable-rate borrowings. Under the terms of the interest rate swap agreement, we receive from the counterparty interest on the notional amount based on one month LIBOR and we pay to the counterparty a fixed rate of 1.500%.

On March 16, 2020, we entered into a forward interest rate swap agreement effective February 28, 2020 and ending February 28, 2025, with a notional amount of \$100.0 million. We entered into this derivative instrument to further hedge against the interest rate risks of our variablerate borrowings. Under the terms of the interest rate swap agreement, we receive from the counterparty interest on the notional amount based on one month LIBOR and we pay to the counterparty a fixed rate of 0.885%.

We also have exposure to changes in interest rates associated with the promissory note assumed on June 30, 2017 in connection with our purchase of an aircraft, which has variable interest rates tied to LIBOR. At September 30, 2021, the outstanding principal amount of the promissory note was \$2.9 million and carried an interest rate of 2.1%. A hypothetical 100 basis point change in this interest rate would not have a material effect on our

pretax income. At December 31, 2020, the outstanding principal amount of the promissory note was \$3.3 million and carried an interest rate of 2.1%. A hypothetical 100 basis point change in the interest rate as of December 31, 2020 would not have had a material effect on our pretax income.

We do not use derivative instruments for trading or other speculative purposes. From time to time, we invest excess cash in short-term marketable securities. These investments principally consist of overnight sweep accounts. Due to the short maturity of these investments, we have concluded that we do not have material market risk exposure.

We have an investment in the form of 1.69% convertible debt in Shorelight Holdings, LLC, a privately-held company, which we account for as an available-for-sale debt security. As such, the investment is carried at fair value with unrealized holding gains and losses excluded from earnings and reported in other comprehensive income. As of September 30, 2021, the fair value of the investment was \$61.5 million, with a total cost basis of \$40.9 million. At December 31, 2020, the fair value of the investment was \$64.4 million, with a total cost basis of \$40.9 million.

We have a preferred stock investment in Medically Home Group, Inc., a privately-held company, which we account for as an equity security without a readily determinable fair value using the measurement alternative. As such, the investment is carried at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment. Any unrealized holding gains and losses resulting from observable price changes are recorded in our consolidated statement of operations. As of September 30, 2021 and December 31, 2020, the carrying value of the investment was \$6.7 million, with a total cost basis of \$5.0 million. Following our purchase, we have not identified any impairment of our investment.

See Note 10 "Fair Value of Financial Instruments" for further information on our long-term investments in Shorelight Holdings, LLC and Medically Home Group, Inc.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of the Company's Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of September 30, 2021. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2021, our disclosure controls and procedures were effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by us in the reports we file or submit under the Exchange Act, and such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended September 30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

The information required by this Item is incorporated by reference from Note 13 "Commitments, Contingencies and Guarantees" included in Part I, Item 1 of this Form 10-Q.

From time to time, we are involved in legal proceedings and litigation arising in the ordinary course of business. As of the date of this Quarterly Report on Form 10-Q, we are not a party to any litigation or legal proceeding that, in the current opinion of management, could have a material adverse effect on our financial position or results of operations. However, due to the risks and uncertainties inherent in legal proceedings, actual results could differ from current expected results.

ITEM 1A. RISK FACTORS.

See Part 1, Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, which was filed with the Securities and Exchange Commission on February 23, 2021, for a complete description of the material risks we face.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

Our Stock Ownership Participation Program, 2012 Omnibus Incentive Plan, and 2004 Omnibus Stock Plan, which was replaced by the 2012 Omnibus Incentive Plan, permit the netting of common stock upon vesting of restricted stock awards to satisfy individual tax withholding requirements. During the quarter ended September 30, 2021, we reacquired 12,489 shares of common stock with a weighted average fair market value of \$49.35 as a result of such tax withholdings.

In November 2020, our board of directors authorized a share repurchase program permitting us to repurchase up to \$50 million of our common stock through December 31, 2021 (the "2020 Share Repurchase Program"). During the third quarter of 2021, our board of directors authorized an extension of the 2020 Share Repurchase Program through December 31, 2022 and increased the authorized amount from \$50 million to \$100 million. The amount and timing of the repurchases will be determined by management and will depend on a variety of factors, including the trading price of our common stock, capacity under our line of credit, general market and business conditions, and applicable legal requirements.

The following table provides information with respect to purchases we made of our common stock during the quarter ended September 30, 2021.

Period	Total Number of Shares Purchased ⁽¹⁾	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs		Dollar Value of Shares that may yet be Purchased under the Plans or Programs ⁽²⁾	
July 1, 2021 - July 31, 2021	2,739	\$	49.15		\$	59,731,354	
August 1, 2021 - August 31, 2021	526,471	\$	48.22	518,045	\$	34,745,565	
September 1, 2021 - September 30, 2021	1,324	\$	49.10	—	\$	34,745,565	
Total	530,534	\$	48.23	518,045			

(1) The number of shares repurchased included 2,739 shares in July 2021, 8,426 shares in August 2021, and 1,324 shares in September 2021 to satisfy employee tax withholding requirements. These shares do not reduce the repurchase authority under the 2020 Share Repurchase Program.

(2) As of the end of the period.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

45

ITEM 6. EXHIBITS.

(a) The following exhibits are filed as part of this Quarterly Report on Form 10-Q.

				Incorporated by Reference			
Exhibit Number	Exhibit Description	Filed herewith	Furnished herewith	Form	Period Ending	Exhibit	Filing Date
10.1	Form of the Huron Consulting Group Inc. 2012 Omnibus Incentive Plan Restricted Stock Unit Agreement.	Х					
31.1	<u>Certification of the Chief Executive Officer, pursuant to Rule</u> <u>13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the</u> <u>Sarbanes-Oxley Act of 2002.</u>	Х					
31.2	<u>Certification of the Chief Financial Officer, pursuant to Rule</u> <u>13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the</u> <u>Sarbanes-Oxley Act of 2002.</u>	Х					
32.1	Certification of the Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.		Х				
32.2	Certification of the Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.		Х				
101.INS	Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.	Х					
101.SCH	Inline XBRL Taxonomy Extension Schema Document	Х					
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document	х					
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document	Х					
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document	Х					
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document	Х					
104	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)	х					

46

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Huron Consulting Group Inc.

(Registrant)

/S/ JOHN D. KELLY

John D. Kelly Executive Vice President, Chief Financial Officer and Treasurer

47

Date: November 2, 2021

HURON CONSULTING GROUP INC. 2012 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT

This RESTRICTED STOCK UNIT AGREEMENT (this "<u>Agreement</u>") is made and entered into as of October 1, 2021 (the "<u>Date of Grant</u>"), by and between Huron Consulting Group Inc., a Delaware corporation ("<u>Huron</u>"), and you (the "<u>Recipient</u>").

WHEREAS, the Compensation Committee of the Board of Directors (the "<u>Committee</u>") has approved the grant to Recipient of Restricted Stock Units pursuant to the Huron Consulting Group Inc. 2012 Omnibus Incentive Plan (the "Plan") as set forth below (which award shall constitute the grant of a Full Value Award);

NOW, THEREFORE, in consideration of the covenants and agreements herein contained, and intending to be legally bound hereby, the parties agree as follows:

- 1. <u>Definitions</u>. Capitalized terms which are not defined herein shall have the meaning set forth in the Plan. In addition, the Recipient's "<u>Termination Date</u>" is the date on which his or her employment with Huron and its Affiliates (collectively, the "<u>Company</u>") terminates for any reason.
- 2. <u>Grant of Restricted Stock Units</u>. Huron hereby grants to Recipient a number of Restricted Stock Units (the "<u>RSUs</u>"), subject to all of the terms and conditions of this Agreement and the Plan. The Recipient's grant details, including the number of RSUs granted, vesting schedule and expiration date, are reflected in the Recipient's Fidelity NetBenefits account.
- 3. <u>Vesting of Restricted Stock Units</u>. All RSUs shall be unvested unless and until they become vested RSUs in accordance with this Section 3. Except as otherwise provided below, the RSUs shall become "<u>Vested RSUs</u>" in accordance with the schedule reflected in the Recipient's Fidelity NetBenefits account for this grant of RSUs; provided, however, that in order for the shares of RSUs to become Vested RSUs, the Recipient must be employed by Huron or one of its Affiliates as of the applicable date that the RSUs are to become Vested RSUs (each a "<u>Vesting Date</u>") except as specifically provided in the Plan or in an Alternative Agreement in effect on the Date of Grant. On the Recipient's death, being Disabled (as defined in the Plan) or Retirement (as defined in the Plan), the RSUs shall be treated as provided under Section 8(b) of the Plan. Subject to the foregoing, any RSUs which are not Vested RSUs on the Recipient's Termination Date shall be forfeited and cancelled and the Recipient shall have no further rights with respect to such RSUs.
- 4. <u>Issuance of Common Stock</u>.

- a. As soon as practicable following each Vesting Date (but in no event later than thirty (30) days after the Vesting Date occurs), Recipient shall be issued one share of Common Stock in settlement of each RSU earned in accordance with <u>Section 3</u>.
- b. Recipient's grant details with respect to RSUs issued hereunder, including the number of RSUs granted and vesting schedule, shall be reflected in Recipient's Fidelity NetBenefits account. Any shares of Common Stock issued may be evidenced by stock certificates, at the request of Recipient, which certificates shall be registered in the name of Recipient and delivered to Recipient within five (5) days of such request.
- 5. <u>Restrictions on Transfer</u>. Except by will or the laws of descent and distribution, Recipient may not sell, assign, pledge or transfer or otherwise dispose of Recipient's RSUs or any rights under or with respect to the RSUs. The rights of Recipient with respect to the RSUs shall not be subject to the claims of creditors of Recipient.
- 6. <u>Adjustment of Award</u>. The number and type of RSUs or shares awarded pursuant to this Agreement shall be adjusted by the Committee in accordance with the Plan to reflect certain corporate transactions which affect the number, type or value of Common Stock.
- 7. <u>Undertakings by Recipient</u>. Recipient hereby agrees to take whatever additional actions and execute whatever additional documents the Committee may, in its discretion, deem necessary or advisable in order to carry out or affect one or more of the obligations or restrictions imposed on Recipient pursuant to the express provisions of this Agreement and the Plan.
- 8. <u>Rights as a Stockholder</u>. Recipient shall not be a stockholder of Huron unless and until shares of Common Stock are issued in settlement of the RSUs and are registered in Recipient's name in accordance with the terms of this Agreement. Huron shall hold in escrow all dividends, if any, that are paid with respect to the RSUs until shares have been issued in respect of such RSUs and all restrictions on such shares have lapsed. Recipient agrees that the RSUs shall not have any voting rights.
- 9. <u>Notices</u>. Any notice required or permitted under this Agreement shall be deemed given when delivered personally, or when deposited within the United States Post Office, postage prepaid, addressed, as appropriate, to Huron at its principal offices, to Recipient at Recipient's address as last known by Huron or, in either case, such other address as one party may designate in writing to the other.
- 10. <u>Securities Laws Requirements</u>. Huron shall not be obligated to transfer any shares of Common Stock from Recipient to another party if such transfer, in the opinion of counsel for Huron, would violate the Securities Act of 1933, as amended from time to time (or any other federal or state statutes having similar requirements as may be in effect at that time). Further, Huron may require as a condition of transfer of any shares of Common Stock in settlement of the RSUs that Recipient furnish a written representation that Recipient is holding the shares for investment and not with a view to resale or distribution to the public.

- 11. <u>Protections Against Violations of Restricted Stock Unit Agreement</u>. No purported sale, assignment, mortgage, hypothecation, transfer, pledge, encumbrance, gift, transfer in trust (voting or other) or other disposition of, or creation of a security interest in or lien on, any of the RSUs by any holder thereof in violation of the provisions of this Agreement or the Certificate of Incorporation or the By-Laws of Huron, shall be valid and Huron will not transfer any of said RSUs on its books nor will any of said RSUs or shares issued in respect of such RSUs be entitled to vote, nor will any dividends be paid thereon, unless and until there has been full compliance with said provisions to the satisfaction of Huron. The RSUs do not constitute shares of Common Stock and Recipient shall not, as a result of this Agreement, be a stockholder of Huron. The foregoing restrictions are in addition to and not in lieu of any other remedies, legal or equitable, available to enforce said provisions.
- 12. <u>Taxes</u>. The award hereunder and any payments or distributions pursuant to the award are subject to withholding of all applicable taxes. Recipient understands that Recipient (and not Huron or any of its Affiliates) shall be responsible for any tax obligations that may arise as a result of the transactions contemplated by this Agreement and shall pay to Huron the amount determined by Huron to be such tax obligation at the time such tax obligation arises. Recipient agrees to indemnify and hold Huron harmless from any tax liabilities resulting from Recipient's receipt of stock under this Agreement. If Recipient fails to make such payment, the number of shares of stock necessary to satisfy the tax obligations shall be withheld from any distribution or vesting of shares hereunder and shall be used to satisfy Recipient's withholding obligations. Without limiting the generality of the foregoing, Huron has the right, but is not obligated, to withhold any shares of Common Stock or cash to satisfy any applicable withholding taxes required by law, to the extent that Huron determines it is required to do so by law.
- 13. <u>Failure to Enforce Not a Waiver</u>. The failure of Huron to enforce at any time any provision of this Agreement shall in no way be construed to be a waiver of such provision or of any other provision hereof.
- 14. <u>Governing Law</u>. This Agreement shall be governed by and construed according to the laws of the State of Delaware without regard to its principles of conflict of laws.
- 15. <u>Amendment and Termination</u>. The Board of Directors may at any time amend or terminate the Plan, provided that, in the absence of written consent to the change by the Recipient, no such amendment or termination may reduce the rights of the Recipient hereunder. Certain adjustments and amendments shall not be subject to the foregoing limitations as described in the Plan.
- 16. <u>Administration</u>. Subject to Section 5 of the Plan, the authority to administer and interpret this Agreement shall be vested in the Committee, and the Committee shall have all the powers with respect to the award hereunder and this Agreement as it has with respect to the Plan. Any interpretation of this Agreement by the Committee and any decision made by it with respect to this Agreement are final and binding on all persons.

- 17. <u>Survival of Terms</u>. This Agreement shall apply to and bind Recipient and Huron and their respective permitted assignees and transferees, heirs, legatees, executors, administrators, and legal successors.
- 18. <u>Agreement Not a Contract for Services</u>. Neither the grant of RSUs nor the issuance of shares of Common Stock pursuant to this Agreement or any other action taken pursuant to this Agreement shall constitute or be evidence of any agreement or understanding, express or implied, that Recipient has a right to continue to provide services as an officer, director, employee or consultant of the Company for any period of time or at any specific rate of compensation or to any right or claim to any benefit under the Plan or this Agreement.
- 19. <u>Severability</u>. If a provision of this Agreement is held invalid by a court of competent jurisdiction, the remaining provisions will nonetheless be enforceable according to their terms. Further, if any provision is held to be overbroad as written, that provision shall be amended to narrow its application to the extent necessary to make the provision enforceable according to applicable law and enforced as amended.
- 20. <u>Incorporation of Plan; Acknowledgement</u>. The Plan is hereby incorporated herein by reference and made a part hereof and the RSUs and this Agreement are subject to all terms and conditions of the Plan. In the event of any inconsistency between the Plan terms and conditions and this Agreement, the provisions of the Plan shall govern. By signing a copy of this Agreement, Recipient acknowledges having received and read a copy of the Plan.

21. <u>Code Section 409A</u>.

a. The Plan and the Awards granted hereunder are intended to be exempt from or comply with the requirements set forth in Code Section 409A, and any regulations and rulings thereunder, so as to avoid the imposition of excise taxes and other penalties under Code Section 409A. In the event that participation in the Plan would subject Recipient to Code Section 409A excise taxes or penalties, the Company and Recipient shall cooperate to amend the terms of the Award to avoid, insofar as possible, such Code Section 409A penalties while minimizing any material and adverse impact of any such amendment upon the economic, tax or accounting implications of the Plan to the Company. For purposes of the Plan, Recipient's termination of employment with the Company, whether voluntary or involuntary, shall be determined by the Committee in accordance with the requirements of Treasury Regulation Section 1.409A-1(h) which defines "separation from service". Recipient's right to receive installment payments pursuant to the terms of the Agreement shall be treated as a right to receive a series of separate and distinct payments. No action or failure by the Company in good faith to act pursuant to this <u>Section 22</u> shall subject the Company to any claim, liability, or expense, and the Company shall not have any obligation to indemnify or otherwise protect Recipient from the obligation to pay any taxes pursuant to Section 409A.

- b. Notwithstanding any provision contained in this Agreement to the contrary, if (i) any payment hereunder is subject to Section 409A of the Code, (ii) such payment is to be paid on account of Recipient's separation from service or termination of employment (within the meaning of Section 409A of the Code) and (iii) Recipient is a "<u>specified employee</u>" (within the meaning of Section 409A(a)(2)(B) of the Code), then such payment shall be delayed, if necessary, until the first day of the seventh month following Recipient's separation from service (or, if later, the date on which such payment is otherwise to be paid under this Agreement).
- 22. <u>Execution of Award Agreement</u>. The award granted to the Recipient pursuant to this Agreement shall be subject to the Recipient's execution and return of this Agreement to Huron or its designee (including by electronic means) and if this Agreement is not so executed and returned prior to the first date on which RSUs become Vested RSUs, the award shall be forfeited in its entirety.

The parties hereto have executed and delivered this Restricted Stock Agreement as of October 1, 2021.

HURON CONSULTING GROUP INC.

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER, PURSUANT TO RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, James H. Roth, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of Huron Consulting Group Inc.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's Board of Directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 2, 2021

By: /s/ JAMES H. ROTH

James H. Roth Chief Executive Officer

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER, PURSUANT TO RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John D. Kelly, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of Huron Consulting Group Inc.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's Board of Directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 2, 2021

By: /s/ JOHN D. KELLY

John D. Kelly Executive Vice President, Chief Financial Officer and Treasurer

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER, PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Huron Consulting Group Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, James H. Roth, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.

Date: November 2, 2021

By: /s/ JAMES H. ROTH

James H. Roth Chief Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished to the Securities and Exchange Commission as an exhibit to the Form 10-Q and shall not be considered filed as part of the Form 10-Q.

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER, PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Huron Consulting Group Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, John D. Kelly, Executive Vice President, Chief Financial Officer and Treasurer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.

Date: November 2, 2021

By: /s/ JOHN D. KELLY

John D. Kelly Executive Vice President, Chief Financial Officer and Treasurer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished to the Securities and Exchange Commission as an exhibit to the Form 10-Q and shall not be considered filed as part of the Form 10-Q.